


Chem Soc Rev

Chemical Society Reviews

rsc.li/chem-soc-rev



ISSN 0306-0012



Cite this: *Chem. Soc. Rev.*, 2024, 53, 6068

Multimodal optoacoustic imaging: methods and contrast materials

Zhenyue Chen,^{ab} Irmak Gezginer,^{ab} Quanyu Zhou,^{ab} Lin Tang,^{ab} Xosé Luís Deán-Ben^{ab} and Daniel Razansky ^{*ab}

Optoacoustic (OA) imaging offers powerful capabilities for interrogating biological tissues with rich optical absorption contrast while maintaining high spatial resolution for deep tissue observations. The spectrally distinct absorption of visible and near-infrared photons by endogenous tissue chromophores facilitates extraction of diverse anatomic, functional, molecular, and metabolic information from living tissues across various scales, from organelles and cells to whole organs and organisms. The primarily blood-related contrast and limited penetration depth of OA imaging have fostered the development of multimodal approaches to fully exploit the unique advantages and complementarity of the method. We review the recent hybridization efforts, including multimodal combinations of OA with ultrasound, fluorescence, optical coherence tomography, Raman scattering microscopy and magnetic resonance imaging as well as ionizing methods, such as X-ray computed tomography, single-photon-emission computed tomography and positron emission tomography. Considering that most molecules absorb light across a broad range of the electromagnetic spectrum, the OA interrogations can be extended to a large number of exogenously administered small molecules, particulate agents, and genetically encoded labels. This unique property further makes contrast moieties used in other imaging modalities amenable for OA sensing.

Received 19th December 2023

DOI: 10.1039/d3cs00565h

rsc.li/chem-soc-rev

^a *Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, University of Zurich, Switzerland.*

E-mail: daniel.razansky@uzh.ch

^b *Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, ETH Zurich, Switzerland*

Introduction

Optoacoustic (OA) imaging, also known as photoacoustic imaging, synergistically combines optical excitation and ultrasound (US) detection to retrieve comprehensive anatomical, functional,



Zhenyue Chen

Zhenyue Chen is a Senior Scientist at the Institute for Biomedical Engineering, University of Zurich and ETH Zurich. He received his PhD degree in Optical Engineering from Beijing Institute of Technology in 2016. During 2016–2019, he worked as a postdoc at the Technical University of Munich and Helmholtz Center Munich, focusing on optoacoustic imaging techniques. His current work involves development of multimodal biomedical imaging approaches combining

optics, optoacoustics and MRI. He has co-authored more than 50 papers in peer-reviewed journals and serves as a reviewer for a variety of journals such as Optics Letters, Optics Express, Journal of Biophotonics, ACS Photonics, IEEE TMI.



Irmak Gezginer

Irmak Gezginer obtained her MSc degree in Electrical Engineering from ETH Zurich in 2021. She is currently a PhD candidate under the supervision of Prof. Daniel Razansky at the University of Zurich and ETH Zurich. Her research focuses on development of multimodal imaging techniques that combine optoacoustic tomography and magnetic resonance imaging to study brain function.




metabolic, and molecular information from biological tissues. The physical principle underlying the technique entails illumination of the tissue of interest with short light pulses, typically of nanosecond duration, followed by thermoelastic expansion and detection of acoustic radiation generated *via* transient light absorption by tissue chromophores (Fig. 1(a)). While the underlying photophonic phenomenon was first described in 1880,¹ rapid development of biomedical applications only commenced at the turn of the 21st century.^{2,3} OA imaging translates the molecular specificity of light into deep-seated areas by

capitalizing on the low scattering of US to break through the depth barriers imposed by light diffusion in living tissues.⁴ The versatile contrast of OA imaging, which is based on optical absorption, allows for sensing and spatially resolving spectrally-distinctive endogenous chromophores essential to biological function, such as hemoglobin in its oxygenated (HbO) and deoxygenated (HbR) forms, melanin, water, collagen, lipids and others (Fig. 1(b)). Due to the strong intrinsic hemoglobin contrast, OA represents a valuable tool to study the evolution of important hallmarks of cancer such as



Quanyu Zhou

Quanyu Zhou serves as a post-doctoral researcher at the Institute for Biomedical Engineering, University of Zurich and ETH Zurich. She obtained her DrSc degree in Electrical Engineering from ETH Zurich in 2024. Her current research focuses on the development of large-scale fluorescence microscopy techniques for functional brain imaging.



Lin Tang

Lin Tang received her BSc degree in Pharmaceutics from Sichuan Agricultural University in 2017 and MSc degree in 2020 from Wuhan University. She is currently working on a PhD dissertation at the Department of Information Technology and Electrical Engineering at ETH Zurich. Her research interests focus on the development of novel contrast agents with strong spectral signatures in the second near-infrared window to enhance the sensitivity, contrast and penetration depth of optoacoustic and fluorescence imaging techniques.



José Luís Deán-Ben

José Luís Deán-Ben has been working in the field of optoacoustic (photoacoustic) imaging since 2010. He currently serves as a senior scientist and group leader at the Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, University of Zurich and ETH Zurich. Previously, he received post-doctoral training at the Institute of Biological and Medical Imaging, Helmholtz Zentrum Munich. He has contributed to

the development of new optoacoustic systems and data processing algorithms and the application of the new imaging methods in cancer research, cardiovascular biology and neuroscience. He has co-authored more than 150 papers in peer-reviewed journals on these topics.



Daniel Razansky

Daniel Razansky holds the Chair of Biomedical Imaging with double appointment at the Faculty of Medicine, University of Zurich and Department of Information Technology and Electrical Engineering, ETH Zurich. He earned PhD in Biomedical Engineering and MSc in Electrical Engineering from the Technion – Israel Institute of Technology and completed post-doctoral training in bio-optics at the Harvard Medical School. Between 2007 and 2018 he was the Director

of Multi-Scale Functional and Molecular Imaging Lab and Professor of Molecular Imaging Engineering at the Technical University of Munich and Helmholtz Center Munich. His Lab pioneered and commercialized a number of imaging technologies, among them the multi-spectral optoacoustic tomography and hybrid optoacoustic ultrasound imaging. He has published over 300 peer-review journal articles and holds 15 patented inventions in bio-imaging and sensing. He is the Founding Editor of Photoacoustics journal and serves on Editorial Boards of a number of journals published by Springer Nature, Elsevier, IEEE and AAPM. He is also an elected Fellow of the IEEE, Optica and SPIE.






Fig. 1 Optoacoustic (OA) imaging and the rationale of combining OA with other bioimaging modalities. (a) Schematic drawing of the working principle underlying OA imaging. (b) Absorption coefficients of major endogenous tissue chromophores at physiologically relevant concentrations as well as representative exogenous contrast agent indocyanine green (ICG). HbO, HbR, melanin (skin), water, lipid and ICG data adapted from <https://omlc.org/spectra/>. Collagen spectrum from ref. 12. (c) The multi-scale nature of OA imaging, covering studies from the microscopic to macroscopic levels. (d) Performance envelope of OA imaging in comparison to other modalities, underpinning its complementary advantages and the need for multi-modality integration.

angiogenesis, hypoxia and hypermetabolism.^{5,6} Furthermore, considering that most substances absorb light across a broad range of the electromagnetic spectrum, the OA interrogations can be extended to a large number of exogenously administered small molecules, particulate agents, as well as targeted, activatable, and genetically-encoded labels.^{7–11}

Following two decades of rapid technological developments, state-of-the-art OA embodiments can visualize life at multiple spatial scales, ranging from subcellular structures to entire organs, with the same type of optical absorption contrast (Fig. 1(c)).^{13,14} Optical-resolution OA microscopy with focused excitation light covers depths within the transport mean free path of photons (~ 1 mm in biological tissues),¹⁰ thus facilitating capillary-level microvascular imaging with a typical

resolution of a few microns, which can further be refined to cover sub-cellular structures.¹⁵ OA mesoscopy uses instead unfocused illumination and broadband focused US detection to overcome the hard penetration-resolution trade-offs in optical imaging, hence enabling high resolution imaging of deep tissues in the diffuse regime of light.^{7,8} Tomographic image acquisition and rendering with multi-element transducer arrays further enable a real-time imaging capability essential for capturing rapid biological dynamics, such as cardiac or neural activity, at the whole-organ level in mice.^{16,17} These unique advantages have attracted growing attention within the biomedical research community, further fostering the development of new theranostic chemical agents.¹⁸

Despite its powerful technical capabilities, OA suffers from several drawbacks, including limited soft tissue contrast and



penetration depth, inevitable trade-offs between penetration and spatial resolution, as well as limited sensitivity and specificity (Fig. 1(d)). More importantly, OA contrast primarily stems from optical absorption, rendering it less sensitive to other contrast mechanisms related to scattering, fluorescence, acoustic, and magnetic properties of tissue. This motivated the combination of OA with other imaging modalities to fully exploit the unique advantages and complementarity of the method toward a more comprehensive understanding of biological processes.

Due to the inherent hybrid optical and acoustic nature of OA, multi-modality efforts have mainly been focused on hybridization with US,^{19–23} fluorescence (FL),^{24–29} and other optical imaging modalities.^{30–38} Recent progress on multimodal OA has also seen promising combinations with magnetic resonance imaging (MRI),^{39–46} X-ray computed tomography (CT),^{14,47,48} single-photon-emission computed tomography (SPECT),^{47,49} or positron emission tomography (PET)^{50–53} to exploit entirely different types of anatomical, functional, and molecular contrast. Multimodal imaging expands the contrast dimension to aid a comprehensive understanding of biological structure and function, at the expense of a more complex design of imaging systems and contrast materials.^{18,25,39,46,54–60} This review delves into hybridization efforts of OA with other imaging modalities, development of multimodal contrast materials, as well as emerging applications in preclinical research and clinical diagnostics.

Merging optoacoustic imaging with ultrasound

OA and US imaging share common advantages, such as the use of non-ionizing radiation, real-time imaging capability, high spatio-temporal resolution, and portability.⁶¹ Both techniques are based on acquisition of time-resolved pressure signals, which facilitates hybridization. While US renders important structural and blood flow contrast, OA provides additional oxygenation and molecular readings both in preclinical and clinical applications.²² Moreover, the dual-modality combination enables more accurate probing into heterogeneous acoustic and optical properties of living tissues, thus improving image reconstruction performance, data quantification and interpretation.^{23,62,63} The synergistic combination with the well-established US technique can further expedite the clinical adoption of the OA technology.

OA-US imaging systems

High-resolution US and OA imaging is based on point-by-point mechanical scanning of a focused transducer *e.g. via* motorized translational stages^{21,64,65} or a slider-crank scanner.⁶⁶ In multimodal OA-US systems, data acquisition is sequentially switched between the OA and US modes. Anatomical US images were reported to extract the contour maps of uneven surfaces to guide dynamic focusing.²¹ The collected US echoes have also been used to remove the multi-reflection artifacts in OA images by assuming an equivalent impulse function.⁶⁷ Generally, dual-modality systems based on single-element transducers for endoscopic^{68,69} and sub-surface⁷⁰ imaging have been reported

and found wide applications in multi-parametric brain imaging,²¹ melanoma staging,⁷¹ or skull bone morphogenesis and angiogenesis^{64,65} in mice.

Dual-modal OA-US tomographic systems operate instead on a macroscopic imaging scale by employing linear^{19,72–75} or concave transducer arrays^{76–79} in conjunction with broad (unfocused) illumination through a fiber bundle or mirrors.⁷³ Dedicated multi-segment array configurations have been proposed to deliver optimal performance in both OA and US modes^{22,80–82} (Fig. 2(a)). Dual-modality imaging with spectrally unmixed HbO and HbR blood components superimposed on pulse-echo US images have extensively been employed in both small animal and clinical investigations (Fig. 2(b)).^{83–86} Several configurations have been reported to combine OA and transmission-mode US imaging, which is additionally capable of rendering speed of sound (SoS) and acoustic attenuation (AA) maps of tissues^{23,87} (Fig. 2(c)). Fully coregistered OA, reflection- and transmission-mode US images of mice were shown to provide highly complementary multi-parametric readings related to disease state and progression in mice, *e.g.* in the context of tumor growth⁸⁶ (Fig. 2(d)) or fatty liver disease.⁸⁷

OA-US contrast agents

Contrast-enhanced OA-US imaging has been achieved with several types of dual-mode contrast agents. These can be broadly classified into two categories: microbubbles and droplets (Table 1). Microbubbles consisting of a gas-shell structure are routinely employed as US contrast agents. OA contrast has been additionally introduced by incorporating optical-absorbing dyes or nanoparticles (NPs), such as black ink, methylene blue, or porphyrin, onto their shell,^{54–56,88} or by encapsulating nanoparticles (*i.e.*, ink, gold nanorods) within a gas cavity.^{89,90} For instance, engineered microbubbles featured with a porphyrin shell have been proposed (Fig. 2(e)), exhibiting peak optical absorption within the near-infrared (NIR) window (Fig. 2(f)). The enhanced OA signal from porphyrin shell microbubbles, when compared to unmodified microbubbles and microbubbles mixed with free porphyrin, confirms their potential as a dual-modal contrast agent (Fig. 2(g)).⁸⁸ Nanodroplets and microdroplets can also be designed as a core-shell structure, characterized by liquid core formed with perfluorocarbon (PFC) or perfluorobutane (PFB). Different types of photo-absorbers, including indocyanine green (ICG), plasmonic NPs, and porphyrin have been integrated into the core^{54,91} or the shell.⁵⁶ Upon exposure to light radiation or high rarefactional pressure,⁵⁶ nanodroplets can undergo a phase change transforming them into microbubbles, thereby enhancing the US contrast (Fig. 2(h)). The small size of these nanodroplets (<200 nm) allows them to extravasate and accumulate in tumor regions *via* the enhanced permeability and retention (EPR) effect.^{92,93} The dual contrast of the accumulated droplets was exploited for a better characterization of the tumor microenvironment (Fig. 2(i)). Besides simple shell structures, multilayer structures have also been employed, as exemplified by hydrogel microdroplets encapsulating conjugated polymer NPs as photo-absorbers.⁵⁹ The NPs generate OA signals while hydrogel-oil-aqueous layers with varied acoustic resistance provide US






Fig. 2 Dual-mode OA and US imaging. (a) Hybrid OA–US imaging probe with a multi-segment array. The linear segment with low inter-element pitch is optimal for B-mode image formation in the pulse-echo US mode whereas lateral concave segments provide broad angular tomographic coverage for accurate OA image rendering. Reprinted with permission from ref. 80. Copyright 2017 AIP Publishing. (b) OA and US images of the human wrist. From left to right: compounded OA–US image along with the maps of HbO and HbR. Reprinted with permission from ref. 83. Copyright 2017 IEEE. (c) Transmission–reflection optoacoustic ultrasound (TROPUS) computed tomography. A full-ring ring array incorporating fiber bundle outputs on both sides was used to hybridize OA tomography with both reflection-mode and transmission-mode US. Reprinted with permission from ref. 23. Copyright 2019 Springer Nature. (d) Representative OA image, reflection-mode US image, transmission-mode SoS image acquired from a cross section of the tumor region in a mouse. Reprinted with permission from ref. 86. Copyright 2020 Elsevier. (e) Schematic of porphyrin shell microbubbles with measured OA spectrum in (f). (g) OA (top) and US (bottom) images of microbubbles without and with porphyrin–lipid in a plastic phantom. Reprinted with permission from ref. 88. Copyright ©2012, American Chemical Society. (h) Design of phase-change porphyrin nanodroplets. (i) Image enhancement of both US and OA images of HT1080 tumor in a chicken embryo before and after injection of porphyrin nanodroplets. Reprinted with permission from ref. 56. Copyright 2015 John Wiley and Sons.

contrast. In addition to tumor imaging, dual-modal OA–US contrast agents have been used for urinary bladder,⁹⁴ and pancreas imaging.⁹¹ Despite promising proof-of-concept studies, many of the reported OA–US contrast agents have not been tested *in vivo*,^{54,88–90} presumably due to biostability or biocompatibility issues. The ongoing development and refinement of these contrast agents remains an active area of research, aiming at

achieving stronger OA and US responses, improved targeting functions, extended circulation time, and biodegradability.

Optoacoustic and fluorescence imaging

FL imaging is a mainstay technique in biological discovery owing to its high sensitivity and specificity in detecting targeted



Table 1 Dual-modal OA–US contrast materials

Modality	Type	Absorber location	Contrast agents	Absorption (nm)	Application	Ref.
OA–US	Microbubbles	OA shell	Methylene blue MBs	675	Urinary bladder (rat)	94
			Black ink MBs	1064		
			Porphyrin shell MBs	700		
	Droplets	OA core	AuMBs	760	Phantom imaging	88
			Encapsulated-ink PLGA MBs	767	Phantom imaging	89
			ICG-loaded PFC nanodroplet	~ 800	Phantom imaging	90
			PAnDs	780	Phantom imaging	54
			Hydrogel-based microdroplets	750	Pancreas (mouse)	95
			Porphyrin nanodroplet	705	Tumor imaging	59

molecular labels and activity indicators. The depth covered with FL microscopy systems is typically restricted to <1 mm, mainly owing to the strong photon scattering in living biological tissues. In contrast, OA imaging maintains high resolution imaging performance at millimeter to centimeter scale depths, owing to the insignificant scattering of US waves relative to light. Nevertheless, OA imaging can greatly benefit from the versatile molecular contrast of FL-based techniques. FL imaging assisted with FDA-approved dyes like ICG is routinely used in the clinics, *e.g.* in ophthalmology or surgical guidance applications. Most optical dyes provide excellent OA contrast,

making them promising candidates for multimodal OA–FL applications.

OA–FL imaging systems

Scanning OA and FL microscopy may share a common excitation path based on focused light beams. Hybrid OA–FL imaging systems then allow for a separate collection of the generated US and FL responses. This can be achieved by placing light sensors and US transducers on the opposite sides of the sample (Fig. 3(a)), which enabled multimodal integration of OA with nonlinear optical microscopy methods, such as two-photon




Fig. 3 Dual-modal OA–FL microscopy. (a) Typical design employing light and US collection from opposite directions. (b) Structure of yellow fluorescence protein (YFP) which was employed to label bipolar cells in the retina. (c) Sectioned retina slice imaging of transgenic mice after superimposing the YFP labeled bipolar cells and the retinal pigment layer acquired with OA microscopy. Reprinted with permission from ref. 98. Copyright 2014 SPIE. (d) System design for dual-modality signal detection from the same direction. An acoustic-optical beam splitter is inserted between the objective and the imaged object. (e) Pd–meso-tetra(4-carboxyphenyl)porphyrin was employed as the probe to image oxygen partial pressure (pO_2). (f) Multiparametric vascular imaging in the mouse ear under hyperoxia and normoxia conditions with a dual-modality OA–CFM system. Top: OA intensity and sO_2 maps. Bottom: FL intensity and pO_2 maps. Reprinted with permission from ref. 100. Copyright 2011 Optica Society.



microscopy (2PM), second-harmonic generation (SHG) microscopy, and third harmonic generation (THG) microscopy.^{96,97} Mechanical scanning is generally used to acquire two-dimensional OA images, while optical scanning with a galvo mirror is the common approach in nonlinear modalities. To this end, OA microscopy has been combined with confocal fluorescence microscopy (CFM) and 2PM based on a commercial FL microscope, thus enabling sectioned retinal slice imaging in transgenic mice. The FL mode was used to detect yellow fluorescence protein (YFP, Fig. 3(b)) labeled bipolar cells, while melanin in the retinal pigmented layer provided the absorption contrast in OA images⁹⁸ (Fig. 3(c)). A different multimodal OA–FL approach employs an epi-illumination approach with both light and US detectors positioned on the same side to facilitate imaging of thicker specimen. It has been implemented with a customized miniaturized US transducer inserted between the objective and the imaged object.²⁹ The compact design employs a high numerical aperture (NA) objective with minimal interference to the US transducer. This hybrid OA–CFM system enabled imaging of 4T1 breast cancer cells labeled with FL proteins in a xenograft tumor model with surrounding vascular network being depicted in the OA mode.²⁹ Another type of the hybrid combination involved the use of a mechanically-scanned acoustic-optical beam splitter, which was inserted between the objective and sample to reflect the generated OA waves while allowing the detection of back-scattered FL⁹⁹ (Fig. 3(d)). By injecting oxygen sensitive Pd–*meso*-tetra(4-carboxyphenyl)porphyrin phosphorescent probe (Fig. 3(e)), mapping of both blood hemoglobin sO₂ and tissue oxygen partial pressure (*p*O₂) has been demonstrated under normoxia and hyperoxia conditions¹⁰⁰ (Fig. 3(f)). The sO₂ map was acquired with dual-wavelength excitation at 570/578 nm (Fig. 3(f), top), which correlated well with the *p*O₂ values derived from the FL lifetime of the probe measured with CFM (Fig. 3(f), bottom). Transparent US transducer (TUT) technology has opened new possibilities for multimodal OA–FL imaging using on-axis excitation, further enabling quadruple modality US, OA, optical coherence tomography (OCT), and FL fusion imaging.¹⁰¹ Optically-transparent micro-ring resonator (MRR)-based US transducers have also been developed,¹⁰² offering high US detection sensitivity, a wide angular detection angle, and miniature (submillimeter) size. Fabrication of a MRR directly on a microscope coverslip facilitated the hybrid OA–CFM microscopic imaging with a commercial inverted microscope platform, which was subsequently used to image retinal pigment epithelium samples *ex vivo* with cellular resolution.¹⁰³

Contrary to scanning FL microscopy, widefield epifluorescence (epiFL) imaging is characterized by high temporal resolution and large (centimeter scale) field-of-view (FOV) matching well those achieved with tomographic OA systems. Yet, a combined OA–epiFL imaging is hampered by the fact that optimal tomographic OA image acquisition implies signal collection over a large angle surrounding the object thus limiting the physical space for recording FL responses. Simultaneous OA–epiFL imaging of thin samples in transmission mode was accomplished with a 60-element hemispherical transducer array and a CCD camera arranged on the opposite

side of the sample.²⁵ More recently, OA–epiFL imaging in reflection mode was achieved using an electron multiplying charge-coupled device (EMCCD)-based fiberscope inserted in a central aperture of a 512-element hemispherical transducer array¹⁰⁴ (Fig. 4(a)). Excitation of both OA and FL responses was performed with a nanosecond pulsed laser that triggered simultaneous EMCCD and US data acquisition. Liposomal ICG was used to achieve contrast-enhanced images of the mouse brain *in vivo* with both modalities and increase the circulation time of free ICG.^{28,104} Combined epiFL and OA imaging of sensory-evoked brain activity has been demonstrated by simultaneously capturing hemodynamics and calcium activity using genetically-encoded calcium indicator GCaMP6f¹⁰⁵ (Fig. 4(b) and (c)). OA–epiFL imaging enabled concurrent measurements of neuronal activity and accompanying hemodynamic responses in mice, thus attaining multiparametric noninvasive characterization of brain activity and neurovascular coupling¹⁰⁶ (Fig. 4(d)–(f)). When combined with A β -targeted probes, such as the luminescent conjugated oligothiophene HS-169 or oxazine dye derivative AOI987, OA–epiFL imaging facilitates transcranial A β detection at multiple scales, all the way from single-plaque resolution in the cortex to whole brain mapping of the plaque load in deep areas such as hippocampus and thalamus¹⁰⁷ (Fig. 4(g) and (h)). Enhancement in tissue penetration and imaging contrast can be achieved for both OA and FL modalities when leveraging the diminished scattering and autofluorescence in the second near-infrared (NIR-II, 1000–1700 nm) range, as has been shown for non-invasive angiography,¹⁰⁸ inflammation detection,¹⁰⁹ tumor diagnosis,^{108,110} and photothermal therapy^{111–113} applications.

OA–FL contrast agents

OA provides label-free contrast based on optical absorption of endogenous substances, such as oxygenated and deoxygenated hemoglobin, melanin, bilirubin, lipids, and water. OA imaging can also visualize FL substances that thermalize part of the absorbed energy.²⁷ Small FL molecules, such as ICG¹¹⁴ or other cyanine dyes^{115,116} having absorption peaks in the NIR spectrum, are ideally suited for synergistically exploiting the advantages of dual-modality OA–FL imaging. The enhanced penetration of light in the NIR range enables tracking specifically-labeled biomolecules in small animals at the whole-body level.¹¹⁷ Both FL and OA signal intensities are proportional to the extinction coefficient (ϵ) of the contrast material. However, FL intensity scales with the quantum yield (QY) while OA intensity is proportional to 1–QY.²⁷ Organic FL dyes with peak absorption in the NIR spectrum commonly exhibit a relatively high ϵ yet low QY, making them particularly suitable for hybrid OA–FL imaging.⁶⁰ Hybrid OA–FL can also be performed with particulate agents, *e.g.* quantum dots (QDs),¹¹⁸ gold nanorods (GNRs),¹¹⁹ carbon nanotubes,¹²⁰ FL silica NPs,¹²¹ or liposomes.¹²² In addition, the use of particles composed of organometallic materials,¹²³ metal-dye composites,¹²⁴ or metal–polymer composites¹²⁵ have also been explored. A list of common OA–FL dual-modal contrast materials appears in Table 2.






Fig. 4 Simultaneous OA and FL imaging for biomedical applications. (a) Schematic of a hybrid OA-epiFL system. Reprinted with permission from ref. 26. Copyright 2017 Optica society. (b) Structure of GCaMP fluorescent protein bound to Ca^{2+} . (c) Absorption spectrum of the GCaMP sensor along with the oxy- and deoxy-hemoglobin spectra. (d), (e) OA and FL activation maps from GCaMP-labeled mouse brain in response to electrical hindpaw stimulation. Reprint with permission from ref. 106. Copyright 2022 John Wiley and Sons. (f) The corresponding fractional signal changes in a selected point. (g) Chemical structure and extinction spectrum of an oxazine dye derivative AOI987 probe for amyloid- β targeting as measured by OA and spectrophotometer along with the oxy- and deoxy-hemoglobin spectra. (h) FL signal of the luminescent conjugated oligothiophene HS-169 signal recorded at single plaque resolution in arca β mouse cortex at 20, 40, 60, 90, and 120 min after dye administration by the large-scale multi-focal illumination (LMI) fluorescence imaging technique. The corresponding OA signal distribution of the oxazine dye derivative AOI987 across the whole mouse brain, as recorded by volumetric multi-spectral optoacoustic tomography (MSOT), is shown in coronal, and horizontal maximal intensity projection (MIP) views. Reprinted with permission from ref. 107. Copyright 2022 Springer Nature.

To this end, the high versatility of OA-FL imaging has been exploited in a number of biomedical applications. A small molecule termed MC-PSE, which is synthesized by utilizing phenylselenophenols to replace the median chlorine atom of an anionic cyanine dye, could self-assemble into J-aggregates in an aqueous solution and disassemble when activated by glutathione. This triggers OA-FL signal fluctuations reflecting the presence of glutathione in cancer.¹²⁷ A synthesized IR780 derivative (IR780-SPhF) also induces ferroptosis-mediated cell

death after accumulating in tumors with a highly elevated glutathione level.¹¹⁶ The reduced light scattering in NIR-II facilitates imaging with deep-tissue. However, design and synthesis of organic probes emitting light in this range remains challenging. NIR-II fluorophores DTP-DPTQ and LET-12 exhibited good performance in imaging-guided photothermal therapy of breast and glioblastoma tumors.^{111,112} Normally, OA-FL dyes have balanced absorption and emission. However, aggregation-induced emission luminogens (MTPE-TT, AIE-



Table 2 Dual-modal OA–FL contrast materials

Modality	Category	Subcategory	Contrast agents	Absorption/ emission (nm)	Application	Ref.		
OA–FL	Organic materials	Small-molecule dyes	PSMAP/ICG NBs	780/820	Prostate cancer	114		
			Cy7-1-maltotriose	750/780	Bacterial infection	115		
			SAPTn	1024/1128	mildPTT, cancer immunotherapy	126		
			MC-PSE	900, 980/940	Glutathione detection	127		
			DTP-DPTQ NPs	852/1120	PTT of breast cancer model	111		
			CySO ₃ -GGT	675/750	Hepatocellular carcinoma	128		
			LET-12	1400/1520	Glioblastoma PTT	112		
			CyA	602/719	PDT, systemic immunotherapy	129		
			IR780-SPhF	780/810	Triple negative breast cancer theranostics	116		
			FMP&N-FMP	680/689	PDT, cancer Immunotherapy	130		
			P-CyPt	700, 750/710	Cancer theranostics	131		
			CTSK-APPA	615, 690/720	Early osteolytic metastasis	132		
			AOI987	650/720	Aβ imaging	107		
			AIEgens	Polymeric nanoprobe	MPNPs	500–800/650–1100	Cancer immunotherapy, type I/II PDT	133
					AIE-4PEG550 NPs	645/900–1700	Kidney fibrosis	134
					C-NTBD NPs	732/1042	Resection of neuroendocrine neoplasms and SLN	135
	EMT-NPs	> 700/643–765			PDX cancer treatment	136		
	SPCy	607, 670/720, 800			Neutrophil elastase	137		
	P2NPs	920/1120			osteosarcoma PTT	138		
	Inorganic materials	Rare-earth doped NPs	CF-SPNs	580, 775/680, 820	Drug-induced hepatotoxicity monitoring	139		
			mPPy@COF-Por	808/501	PDT, PTT of colorectal carcinoma	131		
			Gd _{0.8} Nd _{1.2} O ₂ S@PVP	680–970/1000–1700	Phantom study	126		
			Noble metals	AuPd-BSA CN	400–800/1100–1500	Dual-PDT synergized enzyme catalytic therapy	140	
				PCD	400–900/450–650	Breast cancer model	141	
			Quantum dots	V ₂ C-TAT@Ex-RGD	1000–1350/422	Nucleus-targeted PTT	142	
				a-Ag _{2–x} Cu _x S QDs	635/~ 820	PTT of murine hepatoma tumor	143	
			Other	AuNNPs–Ag ₂ S Ve	400–1200/1250	RT of breast cancer model	110	
		mdGC		510, 798/480	PTT of breast cancer model	144		
		HSC-2		400–1000/957	PTT/catalytic synergistic therapy	113		
		PhAg NPs		680, 850/675, 730	Chemo-PTT melanoma therapy	123		
		Hybrid materials	Organometallic materials	CFNPs	760/780–840	Photothermal primed CDT	124	
				Cy5-conjugated PEG@AgIONPs	680–924/640	PTT, Thrombosis	145	
Metal-dye composites				Au ⁰ -Por@FeCO nanosheets	200–1000/630–800	PTT-gas therapy of breast cancer model	125	
				Other	AHZ NPs	744/1000–1700	PTT in deep tumors	146
MTCNs			1048/1080, 1550		H ₂ O ₂ imaging, lymphatic metastasis	147		
CRUN	663/545, 655		Tumor microenvironment		148			
HCy5/Cy7-UCNs	640, 780/660–800 (tunable)		Multiple ROS/RNS species sensing		149			

4COOH and C-NTBD) feature boosted FL and OA intensity simultaneously, benefiting multifunctional image-guided self-synergistic immunotherapy,¹³³ early diagnosis of renal dysfunction (Fig. 5(a) and (b)),¹³⁴ accurate detection of neuroendocrine neoplasms, and intraoperative sentinel lymph nodes (SLNs) dissection.¹³⁵ Contrary to small molecules, semiconducting polymer particles offer structural flexibility for efficient design of activatable OA–FL probes. For example, semiconducting polymer nanoprobe SPCy initiates its OA and ratiometric FL imaging after reacting with tumor-associated neutrophils.¹³⁷ In addition, the first reported covalent organic framework (COF)-based biomimetic nanomotor composed of a polypyrrole (PPy) core and a porphyrin–COF shell provided a new design strategy of a single multifunctional platform for imaging-guided combined photothermal therapy (PTT) and photodynamic therapy (PDT).¹³¹

Compared with organic contrast agents, the multimodal OA–FL inorganic materials, including Rare-earth (RE) particles, carbon dots, QDs, and noble nanocomposites, are of interest due to their good photostability, broad absorption band, and long FL lifetime. Rare-earth oxysulfide (Gd₂O₂S) NPs have

shown excellent optical performance and low cytotoxicity.¹²⁶ Vanadium carbide (V₂C) QDs modified with TAT peptides and packaged into engineered exosomes could realize nucleus targeting and further destroy tumor cells by low-temperature photothermal therapy.¹⁴² Ultrasmall carbon dots without excess modification could further penetrate deeper into tumors for improved therapeutic outcomes.¹⁴¹ As a novel multifunctional agent, AuPd-BSA CN benefited from its strong NIR absorption and FL intensity in the NIR-II spectrum to guide type I/type II PDT performance. Furthermore, different types of inorganic materials have been integrated together for dual-modal OA–FL imaging in the NIR-II window, such as zeolite-carbon-based nanozymes and nanogapped gold nanoparticles (AuNNPs)–silver sulfide (Ag₂S) vesicles. These enabled prolonged blood circulation times and enhanced tumor accumulation, thus providing enhanced diagnostic information with high resolution (Fig. 5(c) and (d)).^{110,113}

Other sophisticated strategies have been explored to develop advanced OA–FL contrast agents. The FL molecule Pheophorbide-a was loaded into silver NPs that could be activated by NIR light to mediate reactive oxygen species (ROS)-dependent apoptotic cell






Fig. 5 OA-FL dual-modal contrast materials and corresponding applications. (a) Schematic illustration of pH-responsive AuNNPs-Ag₂S Ve used for activatable FL and OA imaging in the NIR-II window. (b) OA images and FL images of MCF-7 tumor-bearing mice after treated with pH-responsive AuNNPs-Ag₂S Ve and nonresponsive AuNNPs-Ag₂S Ve through tail vein injection. Reprinted with permission from ref. 110. Copyright 2022 John Wiley and Sons. (c) Molecular design philosophy of self-assembly ultrasmall AIE-4PEG550 NPs and the reconciled photophysical processes. (d) Representative FL and OA images of the bladder of living mice at preinjection, 4, 60 and 180 min after injection of AIE-4PEG550 NPs. Reprinted with permission from ref. 150. Copyright 2022 John Wiley and Sons. (e) and (f) Structure and bright-field TEM image of Au⁰-Por@FeCO nanosheets. (g) Ex vivo fluorescence imaging of 4T1 tumor-bearing mice after intravenous injection of Au⁰-Por. (h) Time-lapse OA images of the 4T1 tumors after intravenous injection of Au⁰-Por suspension. Reprinted with permission from ref. 125. Copyright 2023 John Wiley and Sons.

death to treat melanomas.¹²³ According to a simple reaction between tetrachloroaurate and *meso*-tetra(pyridyl)porphyrin hydrochloric solution, Au⁰-Por nanosheets served as the carrier

of carbon monoxide-releasing molecules for image-guided gas therapy. The time-to-peak delay of the OA/FL signals between the kidneys and tumor indicates that the nanosheets are accumulated



in the tumor by passive targeting, while the quick degradation and excretion by digestive organs corroborates their biodegradability and improved biosafety (Fig. 5(e)–(h)).¹²⁵ Liposomes, approved as a drug delivery system for clinical use, have been widely used to load drugs, dyes, DNA, and other molecules for multifunctional applications. Through loading of Fe²⁺, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)diammonium salt, citric acid, and polyethylene glycol (PEG)-modified lanthanide down-conversion nanophosphors in the aqueous core and encapsulating IR1048 in the lipid bilayer, liposome-based microenvironment-tailored catalytic nanoprobe were allowed to do accurate and sensitive detection of H₂O₂ *in vivo* via bimodal OA–FL ratiometric imaging in the NIR-II window.¹⁴⁷ Different from conventional contrast materials employing “on or off” concept, the lanthanide-doped upconversion nanocrystals (UCNs) have been extensively applied in biosensing, molecular imaging, and nanomedicine. Owing to their extraordinary capability to convert NIR photonic excitations into multiplexed emissions ranging from ultraviolet to NIR windows, UCNs can ideally realize a precise interrelation and meet complex biological demands by fitting different sensing moieties into one rationally integrated nanomatrix to simultaneously read out numerous analytes, *e.g.* ROS and reactive nitrogen species (RNS), in highly complex and dynamic living environments.^{139,148,149,151} By taking advantages of multiplexing luminescence of UCNs and two specific ROS- and RNS-sensitive NIR cyanine fluorophores, simultaneous screening of various redox species and dynamic profiling of their intricate correlations with pathophysiological implications was achieved.¹⁴⁹

Optoacoustic microscopy and optical coherence tomography

OA microscopy and OCT share a number of common and complementary features in terms of contrast, penetration depth, and spatial resolution, so that more comprehensive tissue characterization is achieved by combining these two modalities. By simultaneously rendering depth-dependent optical scattering profiles, volumetric structural information, chromophore bio-distribution maps, flow velocity values, polarization properties, and temperature maps, the combination between OA and OCT can impact a broad range of applications in oncology, neurology, dermatology, and ophthalmology, both in preclinical and clinical settings.^{35,57,152–155}

OA–OCT imaging systems

Much like for OA–FL imaging, early implementation of hybrid OA and spectral domain OCT was achieved in transmission mode with light delivery and US detection performed from the opposite sides of a thin sample. Light was coupled into the platform through a single-mode optical fiber and focused into the object with a microscope objective.¹⁵² In contrast, reflection mode (epi-illumination) OA–OCT systems share the same optical scanning method for both OA and OCT, with an US detector positioned at the same side to enable an intrinsically-registered imaging performance, as demonstrated *e.g.* by simultaneous

visualization of the microanatomy and microvasculature of the mouse ear *in vivo* (Fig. 6(a)–(d)).³⁴ The opacity of standard US transducers poses challenges for the hybridization between OCT and OA, which was typically achieved by positioning an unfocused US transducer obliquely with respect to the optical axis (Fig. 6(a)), thus causing loss of sensitivity for OA signal detection. A modified design of an akinetic sensor with a large translucent imaging window and a thickness of only 1 mm was reported for dual-modal OA–OCT. The *in vivo* images of zebrafish larvae produced with this system demonstrate its potential in biomedical research (Fig. 6(e) and (f)). Alternatively, TUTs represents a promising avenue for hybridizing OA imaging with other optical imaging methods by enabling on-axis excitation and detection, as previously described in the hybrid OA–FL section. In the same work, seamless integration between US, OA, OCT, and FL imaging was reported based on co-axial illumination through a TUT, further incorporating a spherical acoustic focusing lens combined with multiple light sources, namely, two pulsed lasers for spectroscopic OA imaging, a continuous wave (CW) laser for FL imaging, and a superluminescent light-emitting diode for OCT.¹⁰¹ This quadruple fusion imaging system was shown to provide multiparametric visualization of ophthalmic injuries and neoplastic lesions in rodents. OA imaging methods are well-established for quantifying blood oxygen saturation, which can be complemented with flow measurements provided by Doppler OCT. This provides a powerful means for characterizing blood flow in cardiovascular diseases, such as stroke, hemorrhages, vascular occlusions, as well as other pathologies with flow stasis such as tumors.^{35,156} It is also expected to open a broad range of applications in studying angiogenesis, tissue inflammatory, or healing responses.

OA–OCT imaging contrast agents

The sensitivity and specificity of both OA and OCT can be improved by adding exogenous contrast agents, thus extending the application scope of both modalities from imaging the intrinsic tissue contrast to specific molecular and cellular observations. Among different types of contrast materials, gold nanoparticles (AuNPs) generate signals detectable with both modalities.^{159,160} Owing to the surface plasmon resonance, AuNPs have unique optical properties including strong optical absorption and scattering, making them excellent candidates for dual-mode OA–OCT imaging. AuNPs also have excellent optical tunability as well as bio-, photo-, and thermal-stability. Physically synthesized gold nanodisks (SANs) have been proposed as dual-modal OA–OCT contrast agents due to the excellent tunability of their optical properties, including resonant wavelengths, absorption-to-scattering ratio, and responsiveness to random incident light. By changing the nanodisk's thickness, it is possible to shift its resonant frequency while maintaining the lateral size and achieve excitation within a broad spectral window (Fig. 6(g)). Furthermore, different-sized disks inside the SAN can interact with different wavelengths of the incident light, as evidenced by the extinction spectrum measured from the SAN aqueous solution and fitted by the






Fig. 6 Hybrid OA–OCT imaging. (a) Schematic of the integrated OCT and OA microscopy system in reflection mode. (b) OCT B-scan of the mouse ear *in vivo*. (c) The corresponding top-view OA image with the dashed line indicating the location of the OCT B-scan slice; (d) fused OCT and OA B-scan images at the same location. Ep, epidermis; De, dermis; Ca, cartilaginous backbone; BV, blood vessels; bar, 200 μm . Reprinted with permission from ref. 34. Copyright 2009 Optica society. (e) Schematic of the reflection mode OA–OCT system based on a rigid akinetic Fabry–Perot etalon; (f) images of a 120 h post-fertilization (hpf) zebrafish larva. Reprinted with permission from ref. 157. Copyright 2017 Optica society. (g) Measured extinction curves of the aqueous solutions of the Au nanodisks. (h) Measurements for the extinction curves of the aqueous solutions of the SANS. (i) *In vivo* application of the SANS for bimodal imaging of chicken embryos. The top two images show OCT images of a 5 day-old developed chick embryo (left) before and (right) after injection of SANS. Bottom row: OA images of (left) the injected SANS only and (right) the injected-SANS overlapped with blood flows. The SANS and vasculature images were observed by illuminating at 650 and 532 nm wavelengths, respectively. Reprinted with permission from ref. 158. Copyright 2017 American Chemical Society.

envelope curve of two Gaussian peaks (Fig. 6(h)). In a chick embryo study SANS could be spectrally differentiated from other tissue chromophores by OA, whilst OCT enabled correlating the NPs distribution profiles with the surrounding tissue structures (Fig. 6(i)).¹⁵⁸ Gold nanoshells are other type of AuNPs have also been used to enhance the OCT contrast in cells and improve microangiographic images. In this way, the signal from the retinal and choroidal vessels in living rabbits was

enhanced by up to 82% and 45% for OA and OCT, respectively.⁵⁷ Importantly, conventional OCT contrast generating moieties such as hemoglobin, gold nanorods and plasmonic NPs,^{161–166} liquid-filled microspheres¹⁶⁷ and absorption-based NIR dyes^{168–170} can also serve as OA contrast agents if made to exhibit suitable light absorption properties. Recently introduced gas vesicles (GVs), a class of naturally evolved gas-filled protein nanostructures, can serve as genetically



Table 3 Dual-modal OA–OCT contrast materials

Modality	Category	Subcategory	Contrast agents	Peak absorption (nm)	Application	Ref.
OA–OCT	Inorganic materials	Gold particles	Stacked gold nanodisks (SANS)	670–830	Chick embryo imaging	158
			PEG–AuNPs	520	Retinal and choroidal blood vessels imaging	57
			Gold nanorod	700	Choroidal neovascularization imaging	155
			Gold nanostars	650	Choroidal neovascularization imaging	154
		Gold clusters	CGNPs (clusters)	650	Choroidal neovascularization imaging	172

encodable OCT contrast agents. GVs have yet to be used for OA imaging, but might be a promising candidate for dual-modal OA–OCT applications as the light absorption of the protein is substantially different from the surrounding aqueous environment.¹⁷¹ A summary of dual-modal OA–OCT contrast agents is provided in Table 3.

Optoacoustic and Raman scattering microscopy

Raman scattering microscopy (RSM) is a well-established technique for detecting both endogenous and exogenous markers with high specificity, based on vibrational and rotational transitions of molecular structures. The relatively weak intrinsic Raman scattering signal can be amplified with the surface-enhanced Raman scattering (SERS) and the surface-enhanced resonance Raman scattering (SERRS) effects. RSM offers complementary molecular contrast when paired with OA imaging. However, concurrent OA–Raman measurements are impeded by several factors. Firstly, due to the small cross-section of Raman scattering, RSM suffers from inherently weak signals, necessitating lengthy integration times for each measurement point whereas OA microscopy recordings over large FOVs are typically done within seconds or minutes. Secondly, in coherent RSM two ultrafast pulsed lasers in femto-second or picosecond range are used while OA usually employs a different type of a nanosecond pulsed laser to effectively induce the OA effect. Finally, RSM and OA have different contrast mechanisms and do not share common information that can facilitate image co-registration. Given the differences in their temporal and spatial resolutions, signal excitation/detection schemes, and contrast mechanisms, OA–Raman imaging has been performed by sequential scanning with both modalities. Most of the recent work in this topic has focused on the development of dual-modal OA–Raman contrast agents, particularly for tumor diagnosis purposes to enhance clinical management of cancer.

OA–Raman contrast agents

To harness the advantages of excellent molecular specificity of Raman imaging and deep penetration of OA imaging, several dual-modal OA–Raman contrast agents have been introduced, primarily in the form of core–shell composites (Table 4). Nanostars for combined SERRS and multi-spectral optoacoustic tomography (MSOT) imaging were produced by encapsulating light-absorbing IR780 dye onto a gold nanostar core (Fig. 7(a)), which resulted in a light absorption peak at ~ 770 nm (Fig. 7(b)). The proposed SERRS–MSOT–nanostars were subsequently employed for dual-mode imaging of glioblastoma tissue sections

(Fig. 7(c) and (d)).³³ GNRs are another type of nanomaterial providing high SERS signal and a tunable optical absorption cross section. When functionalized with SERS reporters such as IR792, the modified GNRs manifest a different Raman spectrum, and the absorption peak could be tuned by changing the aspect ratio and particle size for optimized OA performance.³⁰ Besides, a ratiometric dual-modal contrast agent, termed AuNNR@MSi–AuNPs, was designed based on a core–satellite nanostructure by incorporating additional standard OA–Raman reporters located on mesoporous silica-coated nanogapped gold nanorods (AuNNRs) for optimal OA and Raman imaging. Specifically, the ratiometric OA–Raman readings between standard reporters (OA: gold nanorod; Raman: 2-naphthalenethiol) and reference reporters (OA: 2,2'-azino-bis 3-ethylbenzothiazoline-6-sulfonic acid; Raman: 4-mercaptobenzoboric acid) facilitate quantitative detection of H₂O₂ in subcutaneous tumor models in mice and knee osteoarthritis in rabbits.¹⁷³ Another approach involves doping polydopamine (PDA) with the semi-conducting polymer PPy on the supportive SiO₂ templates, shown in Fig. 7(e). PDA offers high absorption and tunes the optical bandgap energy for enhanced Raman signals and diminished FL background due to the resonance Raman effect. Both macromolecules are deposited on a SiO₂ template to form a SiO₂–CS@PPy–PDA nanoparticle, using chondroitin sulfate as the stabilizer. The enhanced OA and Raman signals were validated in images of tumor regions in A549-tumor-bearing mice (Fig. 7(f) and (g)).

Combining optoacoustic and magnetic resonance imaging

Magnetic resonance (MR) imaging is a well-established anatomical and functional imaging tool featured with excellent soft tissue contrast and whole-body coverage, both in small animals and humans. As a non-invasive and non-ionizing modality, it is widely used in preclinical and clinical applications and is often the method of choice in oncological and brain investigations.¹⁷⁴ Like any other imaging modality, MRI is afflicted with a number of shortcomings, including high procurement and maintenance costs, slow imaging speed for high-resolution interrogations, and limited molecular sensitivity. Functional MR imaging (fMRI) based on the blood-oxygen-level-dependent (BOLD) signal has become the gold standard to study brain function. Likewise, fMRI suffers from limited ability to capture fast neuronal responses owing to the indirect hemodynamic readings provided by the BOLD signal.¹⁷⁵ Advanced molecular MRI approaches have been proposed, yet failing to provide high spatio-temporal resolution readings with adequate sensitivity.¹⁷⁶ In contrast, OA offers fast imaging performance with higher molecular



Table 4 Hybrid OA-Raman contrast materials

Modality	Category	Subcategory	Contrast agents	Absorption (nm)	Application	Ref.
OA-Raman	Organic materials	Polymeric nanoprobe	SiO ₂ -CS@PPy-PDA	650	Tumor imaging	32
	Inorganic materials	Nobel metals	AuNNR@MSi-AuNPs	750	Tumor, knee osteoarthritis	173
	Hybrid materials	Metal-dye complexes	SERRS-MSOT-nanostars	770	Tumor imaging (glioblastoma)	33
		Other	GNR with SERS reporter	661/698/756	Tumor imaging (ovarian cancer)	30




Fig. 7 OA-Raman dual-modal contrast materials and corresponding applications. (a) Transmission electron microscopy image of SERRS-MSOT-nanostars. (b) The corresponding optical absorption spectrum of the nanostars. (c) and (d) MSOT and SERRS imaging of the nanostars in a glioblastoma (GBM) tissue section. Reprinted with permission from ref. 33. Copyright 2018 John Wiley and Sons. (e) Schematic of SiO₂-CS@PPy-PDA nanoparticle and its energy transfer model. (f) OA image of the tumor region before and after the intratumoral injection of SiO₂-CS@PPy-PDA in an A549-tumor-bearing mouse under 700 nm illumination. (g) Raman image of a resected tumor tissue, acquired with 785 nm excitation. Reprinted with permission from ref. 32. Copyright 2018 American Chemical Society.

sensitivity but limited penetration depth and relatively poor soft tissue contrast. Powerful complementary advantages could therefore be unlocked with dual-modal OA-MR imaging. The excellent soft tissue contrast provided by MR may serve as anatomical reference for OA, while the multiparametric hemodynamic readings retrieved with OA can complement and cross-validate the BOLD signal, which is currently assumed to be primarily sensitive to deoxygenated hemoglobin. Generally, this multimodal approach can impact many biomedical research fields and improve the diagnostic and therapeutic monitoring capabilities of the standalone modalities *e.g.* in breast cancer or cardiovascular disease imaging applications. Considering that OA has recently been shown capable of imaging the human brain,^{177,178} the multimodal OA-MR combination may potentially have an impact on clinical neuroscience.

OA-MR imaging systems

The high magnetic field strength used by MR scanners combined with the strong field gradients generated by radio-

frequency (RF) pulses hampers efficient implementation of the dual-modality OA and MR imaging, which has mainly been achieved *via* stand-alone acquisitions.^{40,44,179–181} Accurate image coregistration is crucial for accurately combining, correlating, and validating the information acquired from independent measurements. This has mostly been performed *via* landmark-based methods from sequentially acquired images.^{42,182} However, coregistration is significantly challenged by differences in orientation and tissue deformations resulting from independent acquisitions. Recently, a fully hybrid magnetic resonance optoacoustic tomography (MROT) scanner has been developed featuring an MR-compatible OA tomography module inserted into a 9.4 T preclinical MR scanner bore (Fig. 8(a)).⁴³ MROT provides concurrent dual-modal *in vivo* anatomical and functional acquisitions, thus averting the complexity of the coregistration problem with simultaneously acquired images.¹⁸³ The mutual interference challenges between the OA and MR acquisitions were mitigated






Fig. 8 Label-free functional OA–MR imaging. (a) Layout of a hybrid magnetic resonance optoacoustic tomography (MROT) scanner enabling concurrent MR and OA readouts. Reprinted with permission from ref. 183. Copyright 2023 Elsevier. (b) Averaged fractional signal intensity changes of BOLD and multi-parametric OA hemodynamic components in the mouse brain following peripheral sensory stimulation. (c) Superposition of the BOLD, HbO, and HbR activation maps onto the mouse brain atlas. The white color indicates the overlapping region of the three components. Reprinted with permission from ref. 45. Copyright 2022 John Wiley and Sons.

via automatic detection of corrupted frames and by using deuterium oxide (heavy water) to couple US waves. Induced hemodynamic responses to an oxygen challenge paradigm were successfully captured with both modalities across the entire mouse brain.⁴³ Additionally, highly-correlated changes in BOLD and OA hemodynamic components (HbO, HbR, HbT and sO₂) (Fig. 8(b)) were observed under an electrical stimulation paradigm.⁴⁵ Stronger percentile changes were measured in the HbO signal (Fig. 8(c)), while BOLD and HbR signals were found to be less sensitive to sensory responses.⁴⁵

OA–MR contrast agents

A variety of probes have been developed to enhance performance of the dual-modal OA–MR imaging (Table 5). Of particular interest are nanomaterials providing high optical absorption and altered T_1 or T_2 relaxation times, such as Gd³⁺ chelates, superparamagnetic iron oxide (SPIO) NPs, manganese(II) chelates, and reporter genes.¹⁸⁴ Triple-modality MR–OA–Raman imaging was achieved with multimodal NPs composed of a gold core covered with Raman active layer and coated with Gd³⁺ (Fig. 9(a)).³¹ These provided a high longitudinal (T_1) relaxation time ($3.0 \times 10^6 \text{ mM}^{-1} \text{ s}^{-1}$), strong optical absorbance ($2.75 \times 10^{10} \text{ cm}^{-1} \text{ M}^{-1}$) peaked at 540 nm (Fig. 9(b)), and a unique Raman signature. Consecutive MR, OA and Raman imaging revealed EPR-based co-localized accumulation of the NPs in murine glioblastomas following intravenous injection (Fig. 9(c)). Whole-brain localization of the tumor was

achieved by MRI, with OA offering high 3D spatial resolution and Raman providing high-sensitivity surface imaging of the tumor margins.

Melanin, an endogenous biomarker for melanoma detection providing strong OA contrast, has also been applied in the dual-modal OA–MR setting.¹⁹⁶ PEGylated melanin NPs (MNPs) were further conjugated with RGD for tumor targeting and chelated to ⁶⁴Cu²⁺ (PET radiolabel) and Fe³⁺ (T_1 contrast agent) ions to form a ⁶⁴Cu–Fe–RGD–PEG–MNP nanoplatform for triple-modality OA–MR–PET imaging (Fig. 9(d)). Hyperintensities in the T_1 -weighted (Fig. 9(e)) and OA images (Fig. 9(f)) were produced at the tumor site. Both MR and OA signals were found to be linear with NP concentration, with OA being superior to MR in terms of detection sensitivity. A myriad of other probes have been developed for dual-mode OA–MR diagnostic imaging, including cobalt NPs,¹⁸⁹ copper sulfide NPs,¹⁸⁶ copper manganese sulfide nanoplates,¹⁸⁷ conjugated polymer iron oxide (CP-IO) NPs,³⁹ SPIO@Au-labeled mesenchymal stem cells (MSCs),⁴⁰ manganese monoxide nanocomposites (MnO@Au NCs),¹⁹⁷ PEGylated melanin and iron ions NPs (Fe³⁺-PEG-MNPs),¹⁹¹ manganese dioxide coated NPs,¹⁸⁰ cobalt core/carbon shell NPs,¹⁹² carbon nanospheres,¹⁹³ caspase-3 activatable Gd-chelated fluorophores,¹⁸⁵ MnO-hyaluronic acid NPs,¹⁸¹ gold/iron oxide (Au–IO) multimetallic NPs¹⁸⁸ and fluorophore–protein complex.¹⁹⁸ The dual-modal agents have been utilized for enhanced visualization of tumors, thrombi, stem cells, and nerve injuries, to name a few representative examples.^{31,44,194}



Table 5 Dual-modal OA–MR contrast materials

Modality	Category	Subcategory	Contrast agents	Peak absorption (nm)	Application	Ref.	
OA-MR	Organic materials	Small molecule	Gd-IR780	790	Tumor apoptosis	185	
		Inorganic materials	Metal sulfide	Cu _{2-x} S NPs	~1160	Cervical cancer	186
				Cu ₂ MnS ₂ NPs	800–1300	PTT of murine sarcoma model	187
	Multimetallic particles		Au-IO NP	530–550	Cell imaging	188	
			SPIO@Au	810	Glioblastoma tumors	40	
			Nanowontons	700	Mouse imaging	189	
			MSIOs	NIR	PTT of hepatocellular carcinoma	190	
		Iron particles		MINPs	NIR	Immunotherapy, PTT of breast cancer model	41
				Fe ³⁺ -PEG-MNP	680–980	MSC labeling	191
		Other		Cobalt at carbon NPs	400–1000	Glioma tumors	192
			Gd-Fe/HCSs	400–1100	Liver imaging	193	
			HA-MnO@MSN NPs	N.A.	Tumor oxygen modulation	181	
	Hybrid materials	Metal–polymer composites		CP-IO	750	Breast tumor imaging	39
			Other	DDNPs	790	Thrombus diagnosis	194
			PB:Mn nanocubes	808	PTT of breast cancer model	195	

Notably, there is a growing interest in the design of dual-modal theranostic probes providing both therapeutic and diagnostic capabilities. PTT is a cancer treatment strategy based on light-absorbing probes converting laser energy into heat to ablate cancer cells with little collateral damage to surrounding healthy tissues. PTT exhibits reduced side effects compared to mainstream cancer treatments like chemotherapy and radiotherapy (RT).¹⁹⁹ Dual-modal OA–MR image-guided PTT with a single theranostic nanoagent offers complementary advantages for precise lesion localization in the murine brain. Furthermore, dual-modal imaging enables monitoring functional parameters of the tumor environment, such as oxygen and hemoglobin levels in response to therapy, thus allowing continuous adjustment of the intervention. Dual-modal OA–MR contrast agents with high photothermal efficiency under laser radiation have been studied for photothermal applications, including Mn²⁺-doped Prussian blue nanocubes,¹⁹⁵ MoS₂/Fe₃O₄ NPs,¹⁹⁰ copper manganese sulfide nanoplates,¹⁸⁷ mesoporous silica NPs hybridized with manganese dioxide NPs,²⁰⁰ and FeSe₂/Bi₂Se₃ nanosheets.²⁰¹ Recently, magnetic responsive immunostimulatory nanoagents (MINPs) were explored for OA–MR image guided PTT on primary tumors and hyperthermia-triggered immunotherapy on distant metastatic tumors. The MINPs were fabricated using a double-emulsion process and involved three key components: (1) SPIO NPs with combined MR, OA, and PTT functionality, (2) cytosine–phosphate–guanine (CpG) oligodeoxynucleotides (ODNs), immunoadjuvants increasing antitumor immunity, (3) monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-polylysine (mPEG-PLGA-PLL) triblock copolymers, which are cationic carriers to encapsulate the aforementioned agents (Fig. 9(g)). MINPs displayed broad absorption spectra, featuring a peak at 262 nm, which is indicative of the characteristic absorption peak of CpG ODNs (Fig. 9(h)). Upon intravenous injection of MINPs and subsequent magnetic targeting with external magnetic field exposure, a rapid increase in OA signals and decrease in T₂-weighted signals were observed and

sustained for 24 h demonstrating the accumulation and retention of the MINPs at the tumor site⁴¹ (Fig. 9(i)).

Multimodal combinations with ionizing imaging techniques

Nuclear medicine imaging methods, such as positron emission tomography (PET) or single-photon-emission computed tomography (SPECT), are molecular imaging techniques that map the biodistribution of extrinsically administered radioactive tracers to provide information on organ function and cellular (metabolic) activity at the whole-body level.^{202,203} Due to their poor anatomical contrast and spatial resolution, these techniques are commonly combined with X-ray computed tomography (CT) that provides the missing anatomical context with high spatial resolution but suffers from low molecular sensitivity.²⁰⁴ Combination between OA and ionizing imaging modalities brings together the functional OA readouts related to blood oxygenation, the 3D whole-body structural information from CT, and other valuable functional and molecular information from PET or SPECT. Considering the widespread use of PET–CT in clinical oncology, OA can further impact clinical cancer diagnosis and treatment monitoring by providing additional information on tumor hypoxia. To this end, such multimodal combinations have been performed with independent measurements from stand-alone scanners.

OA and X-ray CT

CT contrast stems from the interaction (attenuation) of X-rays and inner-shell electrons. Thereby, probes containing elements with a high atomic number (commonly iodine or barium) are frequently used as CT contrast agents in clinical settings.²⁰⁵ Diverse dual-modal OA–CT diagnostic and theranostic agents have been extensively explored (Table 6). In all cases, multimodal imaging has been realized sequentially with preclinical OA and CT scanners. PEGylated tungsten disulfide nanosheets






Fig. 9 Contrast enhanced OA–MR dual-modal imaging. (a) Structure of a triple-modality OA–MP–Raman NP. (b) Its corresponding optical absorption spectrum. (c) Triple-modality *in vivo* OA–MR–Raman imaging before and after injection of the NP. Reprinted with permission from ref. 31. Copyright 2012 Springer Nature. (d) Synthesis of ^{64}Cu -Fe-RGD-PEG-MNP nanoplatform for triple modality OA–MR–PET imaging. (e) OA imaging of mice bearing U87MG tumors *in vivo* pre- and postinjection of ^{64}Cu -Fe-RGD-PEG-MNP. (f) T_1 -weighted MRI and pseudo-colored MRI *in vivo* pre- and postinjection of ^{64}Cu -Fe-RGD-PEG-MNP. Reprinted from with permission ref. 196. Copyright 2014 American Chemical Society. (g) Synthesis of MINPs (CpG@PLGA-PLL-mPEG/SPIO). (h) Optical absorption spectra of the free CpG ODNs, MNPs (without CpG ODNs) and MINPs. (i) Dual-modal OA and T_2 -weighted MR images at different time points following injection of MINP with and without application of an external magnetic field. Reprinted with permission from ref. 41. Copyright 2019 Elsevier.

(WS_2 -PEG) have been reported as dual-modal OA–CT contrast agents. The synthesis procedure involves fabrication of single-layered WS_2 nanosheets from bulk WS_2 by means of the Morrison method²⁰⁶ and a subsequent surface coating with lipolic acid conjugated PEG (Fig. 10(a)). The probe was shown to provide high NIR-absorbance (Fig. 10(b)) and high X-ray attenuation.²⁰⁷ *In vivo* CT imaging of mice bearing 4T1 breast

tumors before and after intratumoral injection of WS_2 -PEG revealed an almost 6-fold enhancement of the CT signal at the tumor site (Fig. 10(c)), while OA signals were enhanced by approximately 5 and 3 times following intratumoral and intravenous injection, respectively (Fig. 10(d)). Hybrid OA–CT imaging of WS_2 -PEG exploited the complementary strength of both modalities. Whole-body imaging achieved with CT was



complemented with the high spatial resolution images of tumor microstructures acquired with OA. In a recent study, titanium carbide embedded in gold nanocomposites ($\text{Ti}_3\text{C}_2@\text{Au}$) were developed to study photothermally-enhanced RT in the NIR-II window.²⁰⁸ The nanocomposites, synthesized by Au growth on the surface of the Ti_3C_2 nanosheets (Fig. 10(e)), displayed high optical absorption for both the NIR-I and the NIR-II windows (Fig. 10(f)). Following intravenous injection of $\text{Ti}_3\text{C}_2@\text{Au}$ to 4T1 tumor bearing mice, enhanced OA signal with maximum at 24 h post-injection was observed at the tumor site, demonstrating the high uptake of the probe due to the EPR effect (Fig. 10(g)). Similarly, increased CT signals 24 h after injection corroborated the OA imaging results (Fig. 10(h)). Blood oxygen saturation measured with OA doubled that of preinjection levels and was maintained for an hour post the NIR-II irradiation (Fig. 10(i)), indicating that the mild photothermal heating could effectively improve the tumor hypoxia microenvironment thus enhance cancer RT performance.²⁰⁸

OA and SPECT imaging

Nanoagents labeled with radionuclides, e.g. ^{125}I ,^{47,216} ^{131}I ,²¹⁴ and $^{99\text{m}}\text{Tc}$ ⁴¹ have been further studied for OA-SPECT hybrid imaging. OA-SPECT-CT probes have been used as diagnostics agents for sentinel lymph node mapping⁴⁷ and tumor imaging,^{214,217} and substantially as theranostics agents to perform image-guided PTT,^{209–213,218,219} combined PTT and RT,^{48,208,220,221} and combined PTT and chemotherapy.²²² A cypate-induced silk nanoagent labeled with $^{99\text{m}}\text{Tc}$ was used for dual-modal OA-SPECT imaging and theranostic applications.⁴⁹ The synthesis procedure consisted in chemically linking the cypate molecule to the amine groups of silk fibroin and subsequent formation of NPs ($\text{Cy}@\text{Silk}$) through self-assembly under alkaline conditions (Fig. 11(a)), which provided strong NIR absorption (Fig. 11(b)). *In vivo* dynamic OA-SPECT imaging of mice bearing osteosarcomas was performed *via* intravenous injection of the radionuclide labeled NP $\text{Cy}@\text{Silk}-^{99\text{m}}\text{Tc}$ (Fig. 11(c) and (d)). OA signals were increased by 4.3-fold at the tumor location 2 h post-injection, demonstrating the accumulation of NPs *via* the EPR effect (Fig. 11(c) and (e)). Similarly, SPECT imaging was realized at 30 min, 2, 6, and 24 h

after injection of $\text{Cy}@\text{Silk}-^{99\text{m}}\text{Tc}$, and a high uptake was observed at the tumor location and through the removal pathway of the nanoagent (Fig. 11(d) and (f)). The OA-SPECT-CT contrast materials are further summarized in Tables 6 and 7.

OA-PET combinations

The PET technique is widely used in disease diagnosis, monitoring responses to therapy, and pharmacokinetic studies. It allows whole-body quantitative tracking of radionuclide-labeled tracers with high sensitivity, but suffers from limited spatial resolution, slow imaging speed, absence of anatomical information, and a need for radionuclide production facility.²⁰³ The low spatial resolution of preclinical PET scanners relative to the size of internal structures in small animals often leads to partial volume effects.²²⁹ The higher resolution of OA imaging can help to better exploit the excellent sensitivity and deep tissue quantitative imaging capacity of PET. OA provides unique oxygenation readouts that can be exploited in a dual-modal OA-PET combination, which has been used e.g. for image-guided cancer therapy, gut imaging, and neuroimaging of amyloid-beta plaque.^{50,51,224,226,228,230}

Positron-emitting radioisotopes, such as ^{64}Cu ^{53,201,223–225,227,230} and ^{18}F ,⁵⁰ have been combined with OA nanoprobe to establish the dual contrast (Tables 6 and 7). IONPs self-assembled on MoS_2 nanosheets labeled with ^{64}Cu ($^{64}\text{Cu}-\text{MoS}_2\text{-IO}(\text{d})\text{PEG}$) (Fig. 12(a)) act as a biocompatible triple-modality OA-PET-MR contrast agent.²²³ This probe exhibits high NIR-absorbance attributed to MoS_2 nanosheets and allowed imaging the distribution and pharmacokinetics of the ^{64}Cu isotope with PET in an animal tumor model (Fig. 12(b)). Similarly, elevated OA signal levels were observed following administration of the probe peaking at ~8 h post injection, thus corroborating tumor retention of the probe (Fig. 12(c)). The whole-body imaging capacity and high sensitivity of PET, combined with the high-resolution functional OA readings, were used for image-guided PTT with 808 nm laser irradiation (0.78 W cm^{-2} , 5 min), resulting in complete tumor ablation. Another notable multimodal nanotheranostic probe is ^{64}Cu -labeled doxorubicin (DOX)-loaded polydopamine (PDA)-

Table 6 OA-CT, OA-SPECT, and OA-PET contrast materials

Modality	Category	Subcategory	Contrast agents	Absorption	Application (nm)	Ref.
OA-CT	Inorganic materials	Nobel metals	$\text{Pd}@\text{Au}$ -PEG	700	PTT of breast cancer model	209
		Semimetals	Bi_2Se_3 NSS	400–900	HeLa tumor, PTT, Chemo	210
			Bi-LyP-1 NPs	200–1100	PTT/RT of breast cancer model	48
	Hybrid materials	Transition-metal dichalcogenides	WS_2 -PEG	700–1000	PTT of breast cancer model	207
		Multimetallic particles	$\text{Ti}_3\text{C}_2@\text{Au}$	700–1000	PTT/RT of breast cancer model	208
		Metal/semimetals-polymer	$\text{TaO}_x@\text{PPy}$ NPs	300–900	PTT of glioma	211
OA-SPECT	Organic materials	Other	Bi@ PPy-PEG NHs	400–900	PTT of breast cancer model	212
		Small molecule	Au@PB NPs	650–900	PTT of colorectal adenocarcinoma	213
			A1094@RGD-HBc	1094	Brain gliomas	214
			$\text{Cy}@\text{Silk}-^{99\text{m}}\text{Tc}$	600–900	PTT of orthotopic osteosarcoma	215
			^{125}I -MB	667	SLN mapping	47
OA-PET	Inorganic materials	Hybrid materials	CPMSN@ ^{125}I -SD	680–860	Brain ischemia treatment	216
		Metal sulfide	^{64}Cu S-NPs	1064	SLN mapping	53
		Other	^{89}Zr -bGMR@MSN(DOX)-PEG	805	Chemo-PTT therapy of breast cancer model	51






Fig. 10 OA–CT dual-modal imaging. (a) Synthesis of WS₂-PEG nanosheets. (b) Optical absorption spectra of WS₂ and WS₂-PEG. (c) CT images of mice pre- and post-intratumoral (i.t.) and intravenous (i.v.) injection of WS₂-PEG. Red dashed circle indicates the tumor and green dashed circle indicates the mouse liver. (d) OA images of murine tumors pre- and post-i.t. or i.v. injection of WS₂-PEG. Reprinted with permission from ref. 207. Copyright 2013 John Wiley and Sons. (e) Synthesis of Ti₃C₂@Au. (f) OA signal intensities in the NIR window for Ti₃C₂ and Ti₃C₂@Au. (g) OA images of tumor-bearing mice at different time intervals following injection of Ti₃C₂@Au. (h) CT images of mice pre- and postinjection of Ti₃C₂@Au. Red dashed circle indicates the tumor location. (i) Blood oxygen saturation images pre- and post-radiation at different time intervals. Reprinted with permission from ref. 208. Copyright 2019 American Chemical Society.

gadolinium-metallofullerene (CDPGM), which was used for OA–PET–MR imaging-guided chemo-photothermal combination therapy.²²⁶ The PDA core of the CDPGM acts as an OA contrast agent with high NIR-absorption and photothermal stability. *In vivo* imaging of U87MG-tumor-bearing mice following intravenous injection of the probe manifested gradually enhanced OA contrast at the tumor site (Fig. 12(d)). The uptake efficiency of the probe within the tumor was measured quantitatively with PET, indicating increased uptake at 24 h postinjection followed by a subsequent decrease (Fig. 12(e) and (f)). OA signal intensity showed a maximum 3-fold increase 24 h post-injection and

decreased at later time points in accordance with the PET results (Fig. 12(f)).

Dual-modal neuroimaging of disease models may enable validating the functional OA readouts with a well-established PET modality. Also, the high spatial resolution and molecular information from OA can enhance the capabilities of PET for accurate diagnosis and localization of lesions. Recent work incorporated a ¹⁸F labeled croconium dye in an amyloid probe ([¹⁸F]-CDA-3) to visualize amyloid beta (A β) deposits in the Alzheimer's disease (AD) murine brain.⁵⁰ The designed OA–PET–FL probe exhibited strong NIR-absorption (Fig. 12(g)) and photothermal efficiency,






Fig. 11 OA-SPECT dual-modal imaging. (a) Synthesis of Cy@Silk-^{99m}Tc nanoagents. (b) Optical absorption and FL spectra of Cy@Silk and free cypate. (c) *In vivo* dynamic OA imaging of osteosarcoma-bearing mice pre- and post-injection of Cy@Silk. Tumor region is indicated by the red dashed area. (d) *In vivo* dynamic SPECT imaging of osteosarcoma-bearing mice at 30 min and 2, 6, and 24 h post-injection of Cy@Silk-^{99m}Tc. Tumor region is indicated by the red dashed area. (e)-(f) OA and SPECT signal intensities at the tumor site at different time points. Reprinted with permission from ref. 49. Copyright 2019 American Chemical Society.

Table 7 Multimodal OA contrast materials

Modality	Category	Subcategory	Contrast agents	Absorption (nm)	Application	Ref.
OA-MR-Raman	Hybrid materials		MPR nanoparticle	540	Brain tumor resection	31
OA-MR-CT	Inorganic materials	Multimetallic composites	MnO@Au NCs	400-1100	Liver cancer model	197
		Other	MnO ₂ -mSiO ₂ @Au NPs	680-1064	PTT/RT in breast cancer model	200
			MPDA-WS ₂ @MnO ₂	300-808	PTT/RT in breast cancer model	221
			Gd ₂ O ₃ /BSA@MoS ₂ -HA NPs	200-900	PTT/RT in breast cancer model	220
	Hybrid materials		Au@MIL-88(Fe)	720	Glioma	217
			Gd-PEG-Bi NPs	700-900	PTT of glioma	219
OA-MR-PET	Inorganic materials		⁶⁴ Cu-MoS ₂ -IO-(d)PEG	400-1000	PTT in breast cancer model	223
	Hybrid materials	Melanin-based particles	⁶⁴ Cu-Fe-RGD-PEG-MNP	300-1000	Glioblastoma	196
			⁶⁴ Cu-MMNs	500-1100	PTT of glioma, γ -irradiation protection	224
			⁶⁴ Cu-AMF	N.A.	Colon cancer, liver cancer	225
		Other	CDPGM NPs	500-900	Chemo-PTT therapy of glioma	226
			⁶⁴ Cu-NOTA-RGO-IONP _{1st} PEG- ^{2nd} PEG	700-1000	Breast cancer model	227
OA-MR-US	Inorganic materials	Iron particles	PBNCs	750	MSC labeling	179
OA-CT-FL	Organic materials		PFOB@IR825-HA-Cy5.5 NPs	870	PTT of colon cancer	218
			Pdots-DOX-iohexol@hydroge	800	Chemo-PTT therapy in breast cancer model	222
OA-PET-FL	Organic materials	Small molecule	[¹⁸ F]CDA-3	798	A β plaque imaging in AD	50
		Other	Pheo ss-InFroMs	~660	Intestine	228
OA-MR-CT-PET	Inorganic materials	Multimetallic composite	⁶⁴ Cu-FeSe ₂ /Bi ₂ Se ₃ -PEG	700-1000	PTT/RT in breast cancer model	201

displaying distinct distribution pattern in transgenic as opposed to wildtype mice (Fig. 12(h)). Time-lapse OA images displayed enhanced signals in cerebral vessels in the brains of transgenic mice predominantly in the sagittal sinus, while the signal intensity remained almost identical in wildtype mice (Fig. 12(j) and (i)). The OA signal intensity ratio between transgenic and wildtype mice peaked at 4 h following injection, suggesting gradual accumulation in the vessels and high binding to the A β plaque.

Conclusions and outlook

Bioimaging techniques have become essential tools in basic and translational research.²³¹ In parallel, contrast materials are being developed for improved visibility of specific tissues, cells, physiological processes, or molecular pathways in health and disease.²³² Each modality comes with specific strengths and weaknesses pertaining to its costs, portability, spatial and



temporal resolution performance, penetration depth, or molecular sensitivity and specificity. A common approach to achieve comprehensive examinations is to integrate different modalities into hybrid (multimodal) imaging systems providing complementary information. The added value of multimodal imaging is manifested *e.g.* with the widespread use of PET-CT scanners in oncology, brain diseases and other fields, where functional (metabolic) information retrieved with PET is fused onto CT anatomical images.²³³ Proper selection of the contrast

agents is essential for attaining optimal multimodal imaging performance. Multiple substances can be administered, *e.g.* to facilitate co-registration of multimodal images by enhancing angiographic contrast.²³⁴ However, multimodal agents with suitable pharmacokinetic properties, which simultaneously provide detectable contrast in all the employed modalities, are generally preferred.

As a relatively new addition to the bioimaging arsenal, OA techniques are experiencing rapid technological progress.




Fig. 12 OA–PET dual-modal imaging. (a) Schematic presentation of ^{64}Cu - $\text{MoS}_2\text{IO}-(\text{d})\text{PEG}$. (b) PET images of mice pre- and post-intravenous injection of ^{64}Cu - $\text{MoS}_2\text{IO}-(\text{d})\text{PEG}$. Blue dashed circle indicates the tumor site. (c) OA images of tumor pre- and post-injection of polydopamine–gadolinium–metallofullerene (PGM) NPs. Reprinted with permission from ref. 223. Copyright 2015 American Chemical Society. (d) OA images of U87MG-tumor-bearing mice pre- and postinjection of PGM NPs. (e) PET images of U87MG tumor-bearing mice at various time points post injection of core–satellite polydopamine–gadolinium–metallofullerene (CPGM) NPs. (f) OA signal intensity changes and time-dependent tumor uptake of CPGM NPs. Reprinted with permission from ref. 226. Copyright 2017 John Wiley and Sons. (g) Absorption spectrum of ^{18}F CDA-3. (h) ^{18}F CDA-3 PET images of wildtype (WT) and transgenic (Tg) mice. (i) OA images of Tg and WT mice postinjection of ^{18}F CDA-3 at different time points. (j) OA signal intensity changes of WT and Tg mice following ^{18}F CDA-3 injection (left axis) and the OA(Tg)/OA(WT) ratio at different time points (right axis). Reprinted with permission from ref. 50. Copyright 2017 Royal Society of Chemistry.



Initially, light absorption properties of the common optical contrast agents have been exploited for contrast-enhanced OA imaging.²³⁵ More recently, the unique advantages of OA imaging are fostering the development of dedicated contrast materials with physical, chemical, and biochemical characteristics tailored to specific applications.^{18,232,235,236} Dissemination of OA imaging systems among biomedical researchers helps crystallizing the key advantages and limitations of this modality with respect to alternative imaging methods, thus reinforcing the need for developing multimodal OA imaging approaches. Here we provide a detailed description of the benefits and challenges associated with state-of-the-art multi-modality systems, contrast materials, and respective applications, including the combinations of OA with US, FL, OCT, Raman, MRI, CT, SPECT, and PET imaging. We delve into specific strengths achieved by merging the information stemming from absorption of photons in biological tissues with complementary imaging contrast mechanisms based on reflection, scattering, and attenuation of US waves, FL emission, proton relaxation, diffusion, and perfusion-weighted contrast in MRI, X-ray attenuation in CT, single-photon or positron-emitting radionuclides in SPECT and PET. Beyond enriching the structural, molecular, functional, and metabolic information retrieved from living tissues, hybridization with other methods can also help solving or mitigating some of the challenges commonly attributed to the OA methods, such as limited imaging depth, image artifacts associated with acoustic heterogeneities, or wavelength-dependent light attenuation adversely affecting the image quantification capacity.

An important advantage of OA imaging is its label-free capacity, *i.e.* the ability to operate based solely on endogenous chromophores such as hemoglobin, lipids, water, collagen, or melanin. The high concentration of hemoglobin in red blood cells enables label-free angiographic imaging as well as monitoring of hemodynamic changes and oxygen saturation, which has provided new insights in neuroscience, oncology, and other fields.^{237,238} However, the strong absorption background by hemoglobin is a double-edged sword that may hamper the detection of other molecules in the presence of blood. Exogenously administered molecules and particulate agents have been used to enhance the performance of stand-alone and multimodal OA imaging.^{18,235} Accumulation of such agents in specific tissues and cells reveals the presence of pathological microenvironments or protein targets. Organic fluorescent dyes are excellent light absorbers thus ideally suited for hybrid OA-FL imaging, while radio-labelled molecules can readily facilitate hybridization with nuclear medicine methods. More flexibility is achieved by capitalizing on the capabilities of modern nanotechnology to produce multiple types of NPs that can improve molecular targeting efficiency or encapsulate multiple contrast substances and/or therapeutic moieties. Nanoparticulate contrast agents are widely used for contrast enhancement in various imaging modalities thus can readily be engineered to exhibit light absorption properties to achieve optimal OA multimodal performance. Larger micrometer-scale particles and microbubbles are commonly used for enhancing

US contrast and enabling super-resolution imaging beyond the acoustic diffraction barrier.²³⁹ Recently, microparticles have also been used to realize similar super-resolution approaches in FL and OA imaging.²⁴⁰⁻²⁴² Further developments in multimodal contrast materials should not only focus on improving their efficiency of signal generation but also optimizing the biodistribution properties, targeting capacity, biodegradability, and biocompatibility to reduce toxicity and administered doses.

Hybridization of OA with other imaging modalities may face technical challenges. OA imaging traditionally requires an opaque transducer array detector to collect signals over a broad angle surrounding the object thus limiting the physical space for signal collection with other modalities. Furthermore, the OA signal sampling electronics emits electromagnetic radiation, potentially interfering with other imaging modalities, such as MRI, where shielding and proper grounding are essential to minimize electromagnetic interference. Besides, coupling media (*e.g.*, water or gel) is commonly required for efficient detection of the generated OA responses, which may introduce additional compatibility issues and image artifacts when combining OA with other modalities. Multimodal system integration also comes with an inevitable cost of higher complexity in terms of the system's hardware design, synchronization of data acquisition, and image interpretation. Nonetheless, with the advent of more affordable lasers and US detection platforms along with new high-performance contrast materials, multimodal OA imaging is expected to find broad applicability in diverse areas, such as oncology, dermatology, neurology, and cardiovascular diseases.

We have shown that multimodal OA approaches can impact a myriad of biomedical research fields. When combined with MRI or US, the simultaneous multi-parametric hemodynamic readings can significantly enhance neuroscience research into resting-state or stimulus-evoked brain activity with FL imaging assisted with calcium or voltage indicators providing additional insights on the neural activity. Combining MRI or CT for anatomical tumor characterization with the functional and molecular contrast offered by OA can enhance oncological research, where multimodal agents further enable therapeutic interventions, *e.g. via* PTT or PDT. The use of high-frame-rate imaging technologies, such as OA, US, or OCT, is essential in cardiovascular biology, where simultaneous imaging with diverse contrast mechanisms can facilitate the study of electro-mechanical wave propagation and cardiac arrhythmias. Verification and cross-validation of experimental results with other imaging methods have also been essential for the wider adoption of OA imaging approaches. This is of particular relevance for successful clinical translation of OA imaging where the physicians trained with well-established clinical imaging methods may lack the knowledge to interpret OA images. Multimodal imaging systems based on hybridization with routinely used clinical approaches can then help identify OA biomarkers of clinical relevance for diagnostic purposes. Multimodal contrast agents with clear OA signatures can also potentially be used in patients. Light-absorbing organic dyes, such as ICG, Evans blue, or Methylene blue, are approved for clinical use,



while contrast-enhanced US, MRI, or CT is also routinely used. This is expected to facilitate the regulatory approval of new hybrid formulations provided the added value of multimodal OA imaging has been demonstrated. All in all, the complementary anatomical, functional, molecular, and metabolic information rendered with multimodal imaging systems facilitates the full exploitation of the unique advantages and complementarity of OA toward a more comprehensive understanding of biological processes.

Abbreviations

NP	Nanoparticle	EMT-NPs	Endoplasmic reticulum and mitochondria dual-targeting nanoparticles
PFC	Perfluorocarbon	PDX	Patient-derived xenograft
MB	Methylene blue	SPCy	Semiconducting polymer conjugated with a hemicyanine (hemi-Cy) dye caged by a NE-cleavable peptide as the side chain
BI	Black ink	P ₂ NPs	Semiconductor polymer P2 encapsulated with amphiphilic PEGylated phospholipid
MSOT	Multi-spectral optoacoustic tomography	CF-SPNs	Semiconducting polymer nanoparticles with fluorescence resonance energy transfer (FRET) and chemiluminescence resonance energy transfer
AuMBs	Albumin-shelled microbubbles with encapsulated gold nanorods	mPPy@COF-Por	Membrane-coated core-shell nanomotor consisting a porphyrin-decorated COF Shell and polypyrrole core
PAnDs	Plasmonic noble metal nanoparticles-encapsulated PFC nanodroplet	AuNNPs-Ag ₂ S Ve	Nanogapped gold nanoparticles (AuNNPs)-silver sulfide (Ag ₂ S) vesicle (Ve)
PSMAP/ICG NBS	Prostate-specific membrane antigen-targeting, indocyanine green-loaded nanobubbles	AgIONPs	Silver-iron oxide nanoparticles
SAPTN	Stimulator of interferon genes agonist-based photoimmunotherapeutic nanomedicine	mdGC	Gold nanorods with carbon-based nanomaterials
MC-PSE	GSH-activatable probe	PCD	Permeable carbon dots
DTP-DPTQ NPs	Fluorophore with dithienopyrrole as the donor and 6,7-diphenyl-[1,2,5]thiadiazolo [3,4-g]quinoxaline as the acceptor	V ₂ C-TAT@Ex-RGD	Vanadium carbide (V ₂ C) QDs PTA modified with TAT peptides and packaged into engineered exosomes (Ex) vector with RGD modification
PTT	Photothermal therapy	PhAg NPs	NIR light absorbing Silver NPs loaded with Pheophorbide-a
RT	Radiotherapy	CFNPs	Croconium dye (Croc)-ferrous ion (Fe ²⁺) nanoprobe
GGT	γ-Glutamyltranspeptidase	CDT	Chemodynamic therapy
LET-12	IR-1064 self-assembly modified with a choline and acetylcholine analogue, 2-methacryloyloxy ethyl phosphorylcholine	Au ⁰ -Por@FeCO	Gold-based porphyrinic coordination polymer nanosheet loaded with triiron dodecarbonyl
CyA	Aminopeptidase N (APN)-activated type I phototheranostic probe	MTCN	Microenvironment-tailored catalytic nanoprobe
FMP&N-FMP	FAPα-activatable molecular pro-theranostic probes organic materials	UCN	Upconversion nanocrystal
P-CyPt	NIR merocyanine fluorophore capped with an ALP-recognition phosphate group (PO ₃ H), a GSH-reducible CDDP prodrug (Pt(IV)), and a hydrophobic D-Phe-D-Phe (FF) dipeptide	CRUN	Enzyme-responsive cross-linking of rare-earth UCNs
CTSK-APPA	Hemicyanine dye (CyN ₃ OH) caged by a cathepsin K (CTSK)-cleavable peptide sequence on one side and functionalized with osteophilic alendronate	HCy5/Cy7-UCNs	Lanthanide-doped upconversion nanocrystals with ROS- and RNS-sensitive NIR cyanine fluorophores
AIEgens	Aggregation-induced emission luminogens	AHZ NPs	Acid-labile metal-organic frameworks with mineralized hyaluronidase (HAase) and encapsulated Ag ₂ S nanodots
MPNPs	AIEgens MTPE-TT and chemotherapeutic drug PTX conjugated with 4-nitrobenzyl chloroformate	HSC-2	Zeolite-carbon-based nanozymes
C-NTBD	Aggregation-induced emission luminogens with benzodithiadiazole as the electron acceptor	MSbNSs	Monodispersed mesoporous Sb nanospheres
		QDs	Quantum dots
		MOF	Metal-organic frameworks
		Nanowontons	Zero-valence ferromagnetic cobalt particles with a gold coating
		CP-IO	Nanocomposites of conjugated polymers and iron oxide nanoparticles
		SPIO@Au nanoparticles	Containing superparamagnetic iron oxide coated with gold



Fe ³⁺ -PEG-MNP	Polyethylene glycol-modified magnetic nanoparticle
MSC	Mesenchymal stem cells
Gd-Fe/HCSs	Hollow carbon nanospheres dotted with GdPO ₄ and γ -Fe ₂ O ₃ nanoparticles
HA-MnO@MSN	Core-shell nanoparticle consists of manganese oxide and hyaluronic acid-conjugated mesoporous silica nanoparticle
Au-IO NP	Gold/iron oxide multimetallic nanoparticles
DDNPs	Dual-modality and dual-ligand nanoparticles
PB	Prussian blue
MSIOs	MoS ₂ /Fe ₃ O ₄ composite
MINPs	Composites of superparamagnetic iron oxide nanoparticles and cytosine-phosphate-guanine oligodeoxynucleotides
NSS	Nanoscale spherical sponges
Bi@PPy-PEG	NHs polyethylene glycol-modified polypyrrole-coated bismuth nanohybrids
Bi-LyP-1	NPs peptide (LyP-1)-labeled ultrasmall semimetal bismuth nanoparticles
CPMSN@ ¹²⁵ I-SD	Cobalt protoporphyrin IX-loaded mesoporous silica nanoparticle with a ¹²⁵ I conjugated/spermine-modified dextran polymer
A1094@RGD-HBc	Mesoionic dye A1094 encapsulated in Arg-Gly-Asp-modified hepatitis B virus core protein (RGD-HBc)
Cy@Silk- ^{99m} Tc	Indocyanine green analogue cypate-induced silk fibroin self-assembly nanoagents
SLN	Sentinel lymph node
MPR nanoparticle	Gold-silica-based SERS nanoparticle coated with Gd ³⁺ ions
MPDA	Mesoporous polydopamine nanosponges
Gd-PEG-Bi NPs	Pure Bi NPs conjugated with gadolinium-diethylenetriaminepentaacetic acid-bis-tetradecylamide
MNP	Melanin nanoparticle
PGM	Polydopamine-gadolinium-metallofullerene
CPGM	Core-satellite polydopamine-gadolinium-metallofullerene
CDPGM	Radionuclide- ⁶⁴ Cu-labeled doxorubicin-loaded polydopamine-gadolinium-metallofullerene core-satellite nanotheranostic agent
⁶⁴ Cu-MMNs	⁶⁴ Cu-labeled magnetic melanin nanoparticles
PBNCs	Prussian blue nanocubes
A β	Amyloid beta
AD	Alzheimer's disease
MINPs	Magnetic responsive immunostimulatory nanoagents
CpG	Cytosine-phosphate-guanine
ODNs	Oligodeoxynucleotides
FOV	Field-of-view
SAN	Stacked gold nanodisk
TUT	Transparent ultrasound transducer

EPR Enhanced permeability and retention

Author contributions

ZC and DR outlined the review content and structure. QZ, LT, ZC, IG, and XLDB drafted the individual sections. DR supervised the work and edited the manuscript. All authors contributed constructively to the manuscript writing and revisions.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

The authors acknowledge grant support from the Swiss National Science Foundation (310030_192757), US National Institutes of Health (UF1-NS107680), Innosuisse – Swiss Innovation Agency (51767.1 IP-LS), Swiss Cancer Research (KFS-5234-02-2021), and Personalized Health and Related Technologies of the ETH Domain (PHRT-582).

References

- 1 S. Manohar and D. Razansky, Photoacoustics: a historical review. *Advances in Optics and Photonics*, *Adv. Opt. Photonics*, 2016, **8**(4), 586–617.
- 2 A. Oraevsky, *et al.*, Laser optoacoustic imaging of the breast: detection of cancer angiogenesis. *BiOS '99 International Biomedical Optics Symposium*. Vol. 3597. 1999: SPIE.
- 3 X. Wang, *et al.*, Noninvasive laser-induced photoacoustic tomography for structural and functional *in vivo* imaging of the brain, *Nat. Biotechnol.*, 2003, **21**(7), 803–806.
- 4 B. Park, *et al.*, Functional photoacoustic imaging: from nano- and micro- to macro-scale, *Nano Convergence*, 2023, **10**(1), 29.
- 5 J. Laufer, *et al.*, *In vivo* preclinical photoacoustic imaging of tumor vasculature development and therapy, *J. Biomed. Opt.*, 2012, **17**(5), 056016.
- 6 A. Ron, *et al.*, Volumetric Optoacoustic Imaging Unveils High-Resolution Patterns of Acute and Cyclic Hypoxia in a Murine Model of Breast Cancer, *Cancer Res.*, 2019, **79**(18), 4767–4775.
- 7 E. C. Cho, *et al.*, Measuring the Optical Absorption Cross Sections of Au–Ag Nanocages and Au Nanorods by Photoacoustic Imaging, *J. Phys. Chem. C*, 2009, **113**(21), 9023–9028.
- 8 G. Kim, *et al.*, Indocyanine-green-embedded PEBBLES as a contrast agent for photoacoustic imaging, *J. Biomed. Opt.*, 2007, **12**(4), 044020.
- 9 D. Razansky, *et al.*, Multispectral opto-acoustic tomography of deep-seated fluorescent proteins *in vivo*, *Nat. Photonics*, 2009, **3**(7), 412–417.



- 10 Z. Zhao, C. B. Swartzchick and J. Chan, Targeted contrast agents and activatable probes for photoacoustic imaging of cancer, *Chem. Soc. Rev.*, 2022, **51**(3), 829–868.
- 11 V. Neuschmelting, *et al.*, Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Photoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation, *Small*, 2018, **14**(23), 1800740.
- 12 S. Sanathana Konugolu Venkata, *et al.*, Diffuse optical characterization of collagen absorption from 500 to 1700 nm, *J. Biomed. Opt.*, 2017, **22**(1), 015006.
- 13 D. Razansky, J. Klohs and R. Ni, Multi-scale optoacoustic molecular imaging of brain diseases, *Eur. J. Nucl. Med. Mol. Imaging*, 2021, **48**(13), 4152–4170.
- 14 L. V. Wang, Multiscale photoacoustic microscopy and computed tomography, *Nat. Photonics*, 2009, **3**(9), 503–509.
- 15 J. Shi, Y. Tang and J. Yao, Advances in super-resolution photoacoustic imaging, *Quant. Imaging Med. Surg.*, 2018, **8**(8), 724–732.
- 16 J. Yao and L. V. Wang, Sensitivity of photoacoustic microscopy, *Photoacoustics*, 2014, **2**(2), 87–101.
- 17 X. L. Deán-Ben, *et al.*, Advanced optoacoustic methods for multiscale imaging of *in vivo* dynamics, *Chem. Soc. Rev.*, 2017, **46**(8), 2158–2198.
- 18 J. Weber, P. C. Beard and S. E. Bohndiek, Contrast agents for molecular photoacoustic imaging, *Nat. Methods*, 2016, **13**(8), 639–650.
- 19 A. Garcia-Uribe, *et al.*, Dual-modality photoacoustic and ultrasound imaging system for noninvasive sentinel lymph node detection in patients with breast cancer, *Sci. Rep.*, 2015, **5**(1), 1–8.
- 20 S. Y. Nam, *et al.*, Combined ultrasound and photoacoustic imaging to noninvasively assess burn injury and selectively monitor a regenerative tissue-engineered construct, *Tissue Eng., Part C*, 2015, **21**(6), 557–566.
- 21 B. Ning, *et al.*, Ultrasound-aided multi-parametric photoacoustic microscopy of the mouse brain, *Sci. Rep.*, 2015, **5**(1), 18775.
- 22 E. Mercep, X. L. Dean-Ben and D. Razansky, Combined Pulse-Echo Ultrasound and Multispectral Photoacoustic Tomography With a Multi-Segment Detector Array, *IEEE Trans. Med. Imaging*, 2017, **36**(10), 2129–2137.
- 23 E. Merčep, *et al.*, Transmission–reflection optoacoustic ultrasound (TROPUS) computed tomography of small animals, *Light: Sci. Appl.*, 2019, **8**(1), 18.
- 24 Y. Wang, *et al.*, Integrated photoacoustic and fluorescence confocal microscopy, *IEEE Trans. Biomed. Eng.*, 2010, **57**(10), 2576–2578.
- 25 I. Kosik and J. Carson, *Combined 3D photoacoustic and 2D fluorescence imaging of indocyanine green contrast agent flow*, SPIE BIOS, vol. 8581. 2013.
- 26 Z. Chen, *et al.*, Hybrid system for *in vivo* epifluorescence and 4D optoacoustic imaging, *Opt. Lett.*, 2017, **42**(22), 4577–4580.
- 27 Z. Chen, *et al.*, Performance of optoacoustic and fluorescence imaging in detecting deep-seated fluorescent agents, *Biomed. Opt. Express*, 2018, **9**(5), 2229–2239.
- 28 Z. Chen, *et al.*, Concurrent fluorescence and volumetric optoacoustic tomography of nanoagent perfusion and bio-distribution in solid tumors, *Biomed. Opt. Express*, 2019, **10**(10), 5093–5102.
- 29 C. Liu, *et al.*, The integrated high-resolution reflection-mode photoacoustic and fluorescence confocal microscopy, *Photoacoustics*, 2019, **14**, 12–18.
- 30 J. V. Jokerst, *et al.*, Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance *via* Raman imaging in living mice, *ACS Nano*, 2012, **6**(11), 10366–10377.
- 31 M. F. Kircher, *et al.*, A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle, *Nat. Med.*, 2012, **18**(5), 829–834.
- 32 Q. Lin, *et al.*, Bandgap Engineered Polypyrrole-Polydopamine Hybrid with Intrinsic Raman and Photoacoustic Imaging Contrasts, *Nano Lett.*, 2018, **18**(12), 7485–7493.
- 33 V. Neuschmelting, *et al.*, Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Photoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation, *Small*, 2018, **14**(23), e1800740.
- 34 S. Jiao, *et al.*, Simultaneous multimodal imaging with integrated photoacoustic microscopy and optical coherence tomography, *Opt. Lett.*, 2009, **34**(19), 2961–2963.
- 35 E. Z. Zhang, *et al.*, Multimodal photoacoustic and optical coherence tomography scanner using an all optical detection scheme for 3D morphological skin imaging, *Biomed. Opt. Express*, 2011, **2**(8), 2202–2215.
- 36 T. Berer, *et al.*, Multimodal noncontact photoacoustic and optical coherence tomography imaging using wavelength-division multiplexing, *J. Biomed. Opt.*, 2015, **20**(4), 46013.
- 37 W. Zhang, *et al.*, High-resolution, *in vivo* multimodal photoacoustic microscopy, optical coherence tomography, and fluorescence microscopy imaging of rabbit retinal neovascularization, *Light: Sci. Appl.*, 2018, **7**, 103.
- 38 Z. Hosseinaee, J. A. Tummon Simmons and P. H. Reza, Dual-Modal Photoacoustic Imaging and Optical Coherence Tomography [Review], *Front. Phys.*, 2021, **8**, 616618.
- 39 Y. Duan, *et al.*, Photoacoustic and Magnetic Resonance Imaging Bimodal Contrast Agent Displaying Amplified Photoacoustic Signal, *Small*, 2018, **14**(42), e1800652.
- 40 Y. Qiao, *et al.*, Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced *via* carotid artery injection, *Nanotechnology*, 2018, **29**(16), 165101.
- 41 Y. Guo, *et al.*, Magnetic-responsive and targeted cancer nanotheranostics by PA/MR bimodal imaging-guided photothermally triggered immunotherapy, *Biomaterials*, 2019, **219**, 119370.
- 42 M. Gehrung, *et al.*, Co-registration of optoacoustic tomography and magnetic resonance imaging data from murine tumour models, *Photoacoustics*, 2020, **18**, 100147.
- 43 Z. Chen, *et al.*, Hybrid magnetic resonance and optoacoustic tomography (MROT) for preclinical neuroimaging, *Light: Sci. Appl.*, 2022, **11**(1), 332.



- 44 J. Ren, *et al.*, A Dual-Modal Magnetic Resonance/Photoacoustic Imaging Tracer for Long-Term High-Precision Tracking and Facilitating Repair of Peripheral Nerve Injuries, *Adv. Healthcare Mater.*, 2022, **11**(13), e2200183.
- 45 Z. Chen, *et al.*, Simultaneous Functional Magnetic Resonance and Photoacoustic Imaging of Brain-Wide Sensory Responses in Mice, *Adv. Sci.*, 2023, **10**(3), e2205191.
- 46 S. Zhang, *et al.*, *In vivo* co-registered hybrid-contrast imaging by successive photoacoustic tomography and magnetic resonance imaging, *Photoacoustics*, 2023, **31**, 100506.
- 47 W. J. Akers, *et al.*, Multimodal sentinel lymph node mapping with single-photon emission computed tomography (SPECT)/computed tomography (CT) and photoacoustic tomography, *Transl. Res.*, 2012, **159**(3), 175–181.
- 48 X. Yu, *et al.*, Ultrasmall Semimetal Nanoparticles of Bismuth for Dual-Modal Computed Tomography/Photoacoustic Imaging and Synergistic Thermoradiotherapy, *ACS Nano*, 2017, **11**(4), 3990–4001.
- 49 Y. Wang, *et al.*, *In Vivo* Photoacoustic/Single-Photon Emission Computed Tomography Imaging for Dynamic Monitoring of Aggregation-Enhanced Photothermal Nanoagents, *Anal. Chem.*, 2019, **91**(3), 2128–2134.
- 50 Y. Liu, *et al.*, Highly specific noninvasive photoacoustic and positron emission tomography of brain plaque with functionalized croconium dye labeled by a radiotracer, *Chem. Sci.*, 2017, **8**(4), 2710–2716.
- 51 C. Xu, *et al.*, Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy, *Biomaterials*, 2018, **165**, 56–65.
- 52 C. Qin, *et al.*, Tyrosinase as a multifunctional reporter gene for Photoacoustic/MRI/PET triple modality molecular imaging, *Sci. Rep.*, 2013, **3**(1), 1–8.
- 53 Q. Liu, *et al.*, 64) CuS-labeled nanoparticles: a new sentinel-lymph-node-mapping agent for PET-CT and photoacoustic tomography, *Contrast Media Mol. Imaging*, 2016, **11**(6), 475–481.
- 54 A. Hannah, *et al.*, Indocyanine Green-Loaded Photoacoustic Nanodroplets: Dual Contrast Nanoconstructs for Enhanced Photoacoustic and Ultrasound Imaging, *ACS Nano*, 2014, **8**(1), 250–259.
- 55 M. Jeon, *et al.*, Methylene blue microbubbles as a model dual-modality contrast agent for ultrasound and activatable photoacoustic imaging, *J. Biomed. Opt.*, 2014, **19**(1), 16005.
- 56 R. J. Paproski, *et al.*, Porphyrin Nanodroplets: Submicrometer Ultrasound and Photoacoustic Contrast Imaging Agents, *Small*, 2016, **12**(3), 371–380.
- 57 V. P. Nguyen, *et al.*, Contrast Agent Enhanced Multimodal Photoacoustic Microscopy and Optical Coherence Tomography for Imaging of Rabbit Choroidal and Retinal Vessels *in vivo*, *Sci. Rep.*, 2019, **9**(1), 5945.
- 58 I. C. Sun, *et al.*, Photoacoustic imaging of cancer cells with glycol-chitosan-coated gold nanoparticles as contrast agents, *J. Biomed. Opt.*, 2019, **24**(12), 1–5.
- 59 Y. Xu, *et al.*, Organic nanoparticle-doped microdroplets as dual-modality contrast agents for ultrasound microvascular flow and photoacoustic imaging, *Sci. Rep.*, 2020, **10**(1), 17009.
- 60 K. Cardinell, *et al.*, A novel photoacoustic-fluorescent contrast agent for quantitative imaging of lymphatic drainage, *Photoacoustics*, 2021, **21**, 100239.
- 61 X. L. Deán-Ben and D. Razansky, Functional optoacoustic human angiography with handheld video rate three dimensional scanner, *Photoacoustics*, 2013, **1**(3), 68–73.
- 62 J. Jose, *et al.*, Speed-of-sound compensated photoacoustic tomography for accurate imaging, *Med. Phys.*, 2012, **39**(12), 7262–7271.
- 63 Y. Zhang and L. Wang, Video-rate full-ring ultrasound and photoacoustic computed tomography with real-time sound speed optimization, *Biomed. Opt. Express*, 2022, **13**(8), 4398–4413.
- 64 W. Li, *et al.*, Tracking Strain-Specific Morphogenesis and Angiogenesis of Murine Calvaria with Large-Scale Optoacoustic and Ultrasound Microscopy, *J. Bone Miner. Res.*, 2022, **37**(5), 1032–1043.
- 65 H. Estrada, *et al.*, Intravital optoacoustic and ultrasound bio-microscopy reveal radiation-inhibited skull angiogenesis, *Bone*, 2020, **133**, 115251.
- 66 C. D. Ly, *et al.*, Development of fast photoacoustic and ultrasound imaging system based on slider-crank scanner for small animals and humans study, *Expert Syst. Appl.*, 2022, **206**, 117939.
- 67 W. Chen, C. Tao and X. Liu, Artifact-free imaging through a bone-like layer by using an ultrasonic-guided photoacoustic microscopy, *Opt. Lett.*, 2019, **44**(5), 1273–1276.
- 68 J.-M. Yang, *et al.*, Simultaneous functional photoacoustic and ultrasonic endoscopy of internal organs *in vivo*, *Nat. Med.*, 2012, **18**(8), 1297–1302.
- 69 X. Dai, *et al.*, Miniature Endoscope for Multimodal Imaging, *ACS Photonics*, 2017, **4**(1), 174–180.
- 70 H. Estrada, *et al.*, Virtual craniotomy for high-resolution optoacoustic brain microscopy, *Sci. Rep.*, 2018, **8**(1), 1459.
- 71 Y. Wang, *et al.*, Toward *in vivo* biopsy of melanoma based on photoacoustic and ultrasound dual imaging with an integrated detector, *Biomed. Opt. Express*, 2016, **7**(2), 279–286.
- 72 G.-S. Jeng, *et al.*, Real-time interleaved spectroscopic photoacoustic and ultrasound (PAUS) scanning with simultaneous fluence compensation and motion correction, *Nat. Commun.*, 2021, **12**(1), 716.
- 73 J. J. Niederhauser, *et al.*, Combined ultrasound and optoacoustic system for real-time high-contrast vascular imaging *in vivo*, *IEEE Trans. Med. Imaging*, 2005, **24**(4), 436–440.
- 74 J. Kim, *et al.*, Multiparametric Photoacoustic Analysis of Human Thyroid Cancers *in vivo* photoacoustic Analysis of Human Thyroid Cancers, *Cancer Res.*, 2021, **81**(18), 4849–4860.
- 75 E. I. Neuschler, *et al.*, A pivotal study of optoacoustic imaging to diagnose benign and malignant breast masses: a new evaluation tool for radiologists, *Radiology*, 2018, **287**(2), 398–412.



- 76 E. Merčep, *et al.*, Hybrid optoacoustic tomography and pulse-echo ultrasonography using concave arrays, *IEEE Trans. Ultrason. Eng.*, 2015, **62**(9), 1651–1661.
- 77 E. Merčep, *et al.*, Whole-body live mouse imaging by hybrid reflection-mode ultrasound and optoacoustic tomography, *Opt. Lett.*, 2015, **40**(20), 4643–4646.
- 78 A. Dima and V. Ntziachristos, In-vivo handheld optoacoustic tomography of the human thyroid, *Photoacoustics*, 2016, **4**(2), 65–69.
- 79 A. Becker, *et al.*, Multispectral optoacoustic tomography of the human breast: characterisation of healthy tissue and malignant lesions using a hybrid ultrasound-optoacoustic approach, *Eur. Radiol.*, 2018, **28**, 602–609.
- 80 X. L. Deán-Ben, E. Merčep and D. Razansky, Hybrid-array-based optoacoustic and ultrasound (OPUS) imaging of biological tissues, *Appl. Phys. Lett.*, 2017, **110**(20), 203703.
- 81 X. Wang, *et al.*, Integrated thermoacoustic and ultrasound imaging based on the combination of a hollow concave transducer array and a linear transducer array, *Phys. Med. Biol.*, 2021, **66**(11), 115011.
- 82 E. Merčep, X. L. Deán-Ben and D. Razansky, Imaging of blood flow and oxygen state with a multi-segment optoacoustic ultrasound array, *Photoacoustics*, 2018, **10**, 48–53.
- 83 E. Merčep, X. L. Deán-Ben and D. Razansky, Combined pulse-echo ultrasound and multispectral optoacoustic tomography with a multi-segment detector array, *IEEE Trans. Med. Imaging*, 2017, **36**(10), 2129–2137.
- 84 F. Knieling, *et al.*, Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity, *N. Engl. J. Med.*, 2017, **376**(13), 1292–1294.
- 85 Erratum for the Research Article: "Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging" by I. Stoffels, S. Morscher, I. Helfrich, U. Hillen, J. Lehy, N. C. Burton, T. C. P. Sardella, J. Claussen, T. D. Poeppel, H. S. Bachmann, A. Roesch, K. Griewank, D. Schadendorf, M. Gunzer and J. Klode, *Sci. Transl. Med.*, 2015, **7**(319), 319er8.
- 86 B. Lafci, *et al.*, Noninvasive multiparametric characterization of mammary tumors with transmission-reflection optoacoustic ultrasound, *Neoplasia*, 2020, **22**(12), 770–777.
- 87 B. Lafci, *et al.*, Multimodal assessment of non-alcoholic fatty liver disease with transmission-reflection optoacoustic ultrasound, *Theranostics*, 2023, **13**(12), 4217–4228.
- 88 E. Huynh, *et al.*, Porphyrin shell microbubbles with intrinsic ultrasound and photoacoustic properties, *J. Am. Chem. Soc.*, 2012, **134**(40), 16464–16467.
- 89 Y.-H. Wang, *et al.*, Photoacoustic/ultrasound dual-modality contrast agent and its application to thermotherapy, *J. Biomed. Opt.*, 2012, **17**(4), 045001.
- 90 C. Kim, *et al.*, Multifunctional microbubbles and nanobubbles for photoacoustic and ultrasound imaging, *J. Biomed. Opt.*, 2010, **15**(1), 010510.
- 91 K. Wilson, K. Homan and S. Emelianov, Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging, *Nat. Commun.*, 2012, **3**, 618.
- 92 K. Greish, Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting, *Methods Mol. Biol.*, 2010, **624**, 25–37.
- 93 J. W. Nichols and Y. H. Bae, EPR: Evidence and fallacy, *J. Controlled Release*, 2014, **190**, 451–464.
- 94 D. Das, *et al.*, On-chip generation of microbubbles in photoacoustic contrast agents for dual modal ultrasound/photoacoustic *in vivo* animal imaging, *Sci. Rep.*, 2018, **8**(1), 6401.
- 95 K. Wilson, K. Homan and S. Emelianov, Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging, *Nat. Commun.*, 2012, **3**(1), 618.
- 96 G. J. Tsevelakis, *et al.*, Hybrid multiphoton and optoacoustic microscope, *Opt. Lett.*, 2014, **39**(7), 1819–1822.
- 97 D. Soliman, *et al.*, Combining microscopy with mesoscopy using optical and optoacoustic label-free modes, *Sci. Rep.*, 2015, **5**(1), 1–9.
- 98 B. Rao, *et al.*, Integrated photoacoustic, confocal, and two-photon microscope, *J. Biomed. Opt.*, 2014, **19**(3), 036002.
- 99 S. Hu, *et al.*, Intravital imaging of amyloid plaques in a transgenic mouse model using optical-resolution photoacoustic microscopy, *Opt. Lett.*, 2009, **34**(24), 3899–3901.
- 100 Y. Wang, *et al.*, *In vivo* integrated photoacoustic and confocal microscopy of hemoglobin oxygen saturation and oxygen partial pressure, *Opt. Lett.*, 2011, **36**(7), 1029–1031.
- 101 J. Park, *et al.*, Quadruple ultrasound, photoacoustic, optical coherence, and fluorescence fusion imaging with a transparent ultrasound transducer, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**(11), e1920879118.
- 102 H. Li, *et al.*, A transparent broadband ultrasonic detector based on an optical micro-ring resonator for photoacoustic microscopy, *Sci. Rep.*, 2014, **4**(1), 1–8.
- 103 B. Dong, *et al.*, Isometric multimodal photoacoustic microscopy based on optically transparent micro-ring ultrasonic detection, *Optica*, 2015, **2**(2), 169–176.
- 104 Z. Chen, *et al.*, Hybrid system for *in vivo* epifluorescence and 4D optoacoustic imaging, *Opt. Lett.*, 2017, **42**(22), 4577–4580.
- 105 S. Gottschalk, *et al.*, Rapid volumetric optoacoustic imaging of neural dynamics across the mouse brain, *Nat. Biomed. Eng.*, 2019, **3**(5), 392–401.
- 106 Z. Chen, *et al.*, Multimodal Noninvasive Functional Neurophotonic Imaging of Murine Brain-Wide Sensory Responses, *Adv. Sci.*, 2022, **9**(24), 2105588.
- 107 R. Ni, *et al.*, Multiscale optical and optoacoustic imaging of amyloid- β deposits in mice, *Nat. Biomed. Eng.*, 2022, **6**(9), 1031–1044.
- 108 B. Guo, *et al.*, Precise Deciphering of Brain Vasculatures and Microscopic Tumors with Dual NIR-II Fluorescence and Photoacoustic Imaging, *Adv. Mater.*, 2019, **31**(30), e1902504.
- 109 Z. She, *et al.*, An NO-responsive probe for detecting acute inflammation using NIR-II fluorescence/optoacoustic imaging, *Chem. Commun.*, 2022, **58**(94), 13123–13126.



- 110 N. Lv, *et al.*, Stimuli-Responsive Hybrid Vesicle for Tumor Dual-Model NIR-II Photoacoustic and Fluorescence Imaging and Precise Radiotherapy, *Adv. Opt. Mater.*, 2022, **10**(17), 2200694.
- 111 P. Xiao, *et al.*, A fluorophore with dithienopyrrole donor for beyond 1300 nm NIR-II fluorescence/photoacoustic dual-model imaging and photothermal therapy, *Mater. Today Nano*, 2023, **24**, 100404.
- 112 F. Zhao, *et al.*, Maximum Emission Peak Over 1500 nm of Organic Assembly for Blood-Brain Barrier-Crossing NIR-IIb Phototheranostics of Orthotopic Glioblastoma, *Adv. Mater.*, 2023, **35**(22), 2208097.
- 113 Z. Zheng, *et al.*, All-in-One Zeolite-Carbon-Based Nanotheranostics with Adjustable NIR-II Window Photoacoustic/Fluorescence Imaging Performance for Precise NIR-II Photothermal-Synergized Catalytic Antitumor Therapy, *Small*, 2021, **17**(41), e2103252.
- 114 Y. Wang, *et al.*, Targeted nanobubbles carrying indocyanine green for ultrasound, photoacoustic and fluorescence imaging of prostate cancer, *Int. J. Nanomed.*, 2020, 4289–4309.
- 115 A. Zlitni, *et al.*, Maltotriose-based probes for fluorescence and photoacoustic imaging of bacterial infections, *Nat. Commun.*, 2020, **11**(1), 1250.
- 116 H. Gan, *et al.*, A Mitochondria-Targeted Ferroptosis Inducer Activated by Glutathione-Responsive Imaging and Depletion for Triple Negative Breast Cancer Theranostics, *Adv. Healthcare Mater.*, 2023, **12**(22), e2300220.
- 117 D. M. Shcherbakova and V. V. Verkhusha, Near-infrared fluorescent proteins for multicolor *in vivo* imaging, *Nat. Methods*, 2013, **10**(8), 751–754.
- 118 Y. Zhao, *et al.*, Amorphous Ag_{2-x}Cu_xS quantum dots: “all-in-one” theranostic nanomedicines for near-infrared fluorescence/photoacoustics dual-modal-imaging-guided photothermal therapy, *Chem. Eng. J.*, 2020, **399**, 125777.
- 119 W. Shang, *et al.*, Core-shell gold Nanorod@metal-organic framework nanoprobe for multimodality diagnosis of glioma, *Adv. Mater.*, 2017, **29**(3), 1604381.
- 120 M. Qian, *et al.*, Highly crystalline multicolor carbon nanodots for dual-modal imaging-guided photothermal therapy of glioma, *ACS Appl. Mater. Interfaces*, 2018, **10**(4), 4031–4040.
- 121 C. Huang, *et al.*, Efficient Photoacoustic Imaging With Biomimetic Mesoporous Silica-Based Nanoparticles, *Front. Bioeng. Biotechnol.*, 2021, **9**, 762956.
- 122 D. Miranda, *et al.*, Highly-soluble cyanine J-aggregates entrapped by liposomes for *in vivo* optical imaging around 930 nm, *Theranostics*, 2019, **9**(2), 381.
- 123 P. M. Patil, *et al.*, Optoresponsive Pheophorbide-Silver based organometallic nanomaterials for high efficacy multimodal theranostics in Melanoma, *Chem. Eng. J.*, 2023, **470**, 144110.
- 124 X. Zhang, *et al.*, Programmably Controllable Delivery of Metastable Ferrous Ions for Multiscale Dynamic Imaging Guided Photothermal Primed Chemodynamic Therapy, *Adv. Mater.*, 2023, 2210876.
- 125 G. Zhou, *et al.*, Renal Clearable Catalytic 2D Au-Porphyrin Coordination Polymer Augmented Photothermal-Gas Synergistic Cancer Therapy, *Small*, 2023, **19**(14), 2206749.
- 126 Q. Zou, *et al.*, PVP-coated ultrasmall Nd-doped Gd₂O₃S nanoparticles for multimodal imaging, *Mater. Chem. Front.*, 2023, 4109–4119.
- 127 Y. Zhao, *et al.*, Reaction-Activated Disassembly of the NIR-II Probe Enables Fast Detection and Ratiometric Photoacoustic Imaging of Glutathione *In Vivo*, *Anal. Chem.*, 2023, 14043–14051.
- 128 K. Wang, *et al.*, Imaging Investigation of Hepatocellular Carcinoma Progress *via* Monitoring γ -Glutamyltranspeptidase Level with a Near-Infrared Fluorescence/Photoacoustic Bimodal Probe, *Anal. Chem.*, 2023, **95**(38), 14235–14243.
- 129 M. Zhao, *et al.*, An Activatable Phototheranostic Probe for Anti-hypoxic Type I Photodynamic- and Immuno-Therapy of Cancer, *Adv. Mater.*, 2023, e2305243.
- 130 H. Zhou, *et al.*, A Tumor-Microenvironment-Activatable Molecular Pro-Theranostic Agent for Photodynamic and Immunotherapy of Cancer, *Adv. Mater.*, 2023, **35**(30), e2211485.
- 131 X. Wen, *et al.*, Controlled sequential *in situ* self-assembly and disassembly of a fluorogenic cisplatin prodrug for cancer theranostics, *Nat. Commun.*, 2023, **14**(1), 800.
- 132 Z. Song, *et al.*, Cathepsin K-Activated Probe for Fluoro-Photoacoustic Imaging of Early Osteolytic Metastasis, *Adv. Sci.*, 2023, **10**(24), e2300217.
- 133 X. Kang, *et al.*, A photo-triggered self-accelerated nanoplat-form for multifunctional image-guided combination cancer immunotherapy, *Nat. Commun.*, 2023, **14**(1), 5216.
- 134 D. Yan, *et al.*, A Water-Soluble AIEgen for Noninvasive Diagnosis of Kidney Fibrosis *via* SWIR Fluorescence and Photoacoustic Imaging, *Adv. Mater.*, 2022, **34**(50), e2206643.
- 135 R. Xu, *et al.*, Highly bright aggregation-induced emission nanodots for precise photoacoustic/NIR-II fluorescence imaging-guided resection of neuroendocrine neoplasms and sentinel lymph nodes, *Biomaterials*, 2022, **289**, 121780.
- 136 W. Wang, *et al.*, A Native Drug-Free Macromolecular Therapeutic to Trigger Mutual Reinforcing of Endoplasmic Reticulum Stress and Mitochondrial Dysfunction for Cancer Treatment, *ACS nano*, 2023, **17**(11), 11023–11038.
- 137 Y. Zhang, *et al.*, An Activatable Polymeric Nanoprobe for Fluorescence and Photoacoustic Imaging of Tumor-Associated Neutrophils in Cancer Immunotherapy, *Angew. Chem., Int. Ed.*, 2022, **61**(27), e202203184.
- 138 C. Zhang, X. Tai, J. Xu, P. Sun, Q. Fan, Z. Cheng and Y. Zhang, 1064 nm activatable semiconducting polymer-based nanoplat-form for NIR-II fluorescence/NIR-II photoacoustic imaging guided photothermal therapy of orthotopic osteosarcoma, *Chem. Eng. J.*, 2022, **445**, 136836.
- 139 A. J. Shuhendler, *et al.*, Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing, *Nat. Biotechnol.*, 2014, **32**(4), 373–380.
- 140 S. Ren, *et al.*, Multifunctional AuPd-cluster nanotheranostic agents with a cascade self-regulating redox tumor-microenvironment for dual-photodynamic synergized



- enzyme catalytic therapy, *J. Mater. Chem. B*, 2023, **11**(1), 109–118.
- 141 Y. Han, *et al.*, Near-infrared-II photothermal ultra-small carbon dots promoting anticancer efficiency by enhancing tumor penetration, *J. Colloid Interface Sci.*, 2022, **616**, 595–604.
- 142 Y. Cao, *et al.*, Engineered exosome-mediated near-infrared-II region V₂C quantum dot delivery for nucleus-target low-temperature photothermal therapy, *ACS Nano*, 2019, **13**(2), 1499–1510.
- 143 Y. Zhao, *et al.*, Amorphous Ag_{2-x}Cu_xS quantum dots: “all-in-one” theranostic nanomedicines for near-infrared fluorescence/photoacoustics dual-modal-imaging-guided photothermal therapy, *Chem. Eng. J.*, 2020, **399**, 125777.
- 144 J. Zhang, *et al.*, A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanof ormulation without External Laser Limitations, *Adv. Mater.*, 2022, **34**(19), 2110690.
- 145 K. X. Vazquez-Prada, *et al.*, A Spiky Silver-Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis, *Small*, 2023, **19**(11), e2205744.
- 146 S. Li, *et al.*, A Two-Pronged Strategy for Enhanced Deep-Tumor Penetration and NIR-II Multimodal Imaging-Monitored Photothermal Therapy, *ACS Appl. Mater. Interfaces*, 2022, **14**(37), 41684–41694.
- 147 T. Chen, *et al.*, Microenvironment-Tailored Catalytic Nanoprobe for Ratiometric NIR-II Fluorescence/Photoacoustic Imaging of H₂O₂ in Tumor and Lymphatic Metastasis, *Adv. Funct. Mater.*, 2022, **32**(47), 2208720.
- 148 X. Ai, *et al.*, *In vivo* covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics, *Nat. Commun.*, 2016, **7**(1), 10432.
- 149 X. Ai, *et al.*, Multispectral optoacoustic imaging of dynamic redox correlation and pathophysiological progression utilizing upconversion nanoprob es, *Nat. Commun.*, 2019, **10**(1), 1087.
- 150 D. Yan, *et al.*, A Water-Soluble AIEgen for Noninvasive Diagnosis of Kidney Fibrosis *via* SWIR Fluorescence and Photoacoustic Imaging, *Adv. Mater.*, 2022, **34**(50), 2206643.
- 151 W. Zheng, *et al.*, Lanthanide-doped upconversion nanobioprobes: electronic structures, optical properties, and biodetection, *Chem. Soc. Rev.*, 2015, **44**(6), 1379–1415.
- 152 L. Li, *et al.*, Three-dimensional combined photoacoustic and optical coherence microscopy for *in vivo* microcirculation studies, *Opt. Express*, 2009, **17**(19), 16450–16455.
- 153 M. Liu and W. Drexler, Optical coherence tomography angiography and photoacoustic imaging in dermatology, *Photochem. Photobiol. Sci.*, 2019, **18**(5), 945–962.
- 154 V.-P. Nguyen, *et al.*, Plasmonic gold nanostar-enhanced multimodal photoacoustic microscopy and optical coherence tomography molecular imaging to evaluate choroidal neovascularization, *ACS Sens.*, 2020, **5**(10), 3070–3081.
- 155 V.-P. Nguyen, *et al.*, Gold nanorod enhanced photoacoustic microscopy and optical coherence tomography of choroidal neovascularization, *ACS Appl. Mater. Interfaces*, 2021, **13**(34), 40214–40228.
- 156 Z. Ma, *et al.*, Assessment of microvasculature flow state with a high speed all-optic dual-modal system of optical coherence tomography and photoacoustic imaging, *Biomed. Opt. Express*, 2018, **9**(12), 6103–6115.
- 157 R. Haindl, *et al.*, Dual modality reflection mode optical coherence and photoacoustic microscopy using an akinetic sensor, *Opt. Lett.*, 2017, **42**(21), 4319–4322.
- 158 J.-S. Wi, *et al.*, Stacked Gold Nanodisks for Bimodal Photoacoustic and Optical Coherence Imaging, *ACS Nano*, 2017, **11**(6), 6225–6232.
- 159 P. Si, *et al.*, Gold nanomaterials for optical biosensing and bioimaging, *Nanoscale Adv.*, 2021, **3**(10), 2679–2698.
- 160 S. Han, R. Bouchard and K. V. Sokolov, Molecular photoacoustic imaging with ultra-small gold nanoparticles, *Biomed. Opt. Express*, 2019, **10**(7), 3472–3483.
- 161 A. Wax and K. Sokolov, Molecular Imaging and Darkfield Microspectroscopy of Live Cells Using Gold Plasmonic Nanoparticles, *Laser Photonics Rev.*, 2009, **3**, 146.
- 162 A. L. Oldenburg, *et al.*, Motility-, Autocorrelation-, and Polarization-Sensitive Optical Coherence Tomography Discriminates Cells and Gold Nanorods within 3d Tissue Cultures, *Opt. Lett.*, 2013, **38**, 2923.
- 163 A. Nahas, *et al.*, Detection of Plasmonic Nanoparticles with Full Field-Oct: Optical and Photothermal Detection, *Biomed. Opt. Express*, 2014, **5**, 3541.
- 164 Y. Jia, *et al.*, Spectral Fractionation Detection of Gold Nanorod Contrast Agents Using Optical Coherence Tomography, *Opt. Express*, 2015, **23**, 4212.
- 165 O. Liba, *et al.*, Contrast-Enhanced Optical Coherence Tomography with Picomolar Sensitivity for Functional *In Vivo* Imaging, *Sci. Rep.*, 2016, **6**, 23337.
- 166 J. Hu, *et al.*, Gold nanoshells: Contrast agents for cell imaging by cardiovascular optical coherence tomography, *Nano Res.*, 2018, **11**(2), 676–685.
- 167 T. M. Lee, *et al.*, Engineered Microsphere Contrast Agents for Optical Coherence Tomography, *Opt. Lett.*, 2003, **28**, 1546.
- 168 C. Xu, *et al.*, Near-Infrared Dyes as Contrast-Enhancing Agents for Spectroscopic Optical Coherence Tomography, *Opt. Lett.*, 2004, **29**, 1647.
- 169 C. Yang, *et al.*, Spectral Triangulation Molecular Contrast Optical Coherence Tomography with Indocyanine Green as the Contrast Agent, *Opt. Lett.*, 2004, **29**, 2016.
- 170 F. E. Robles, *et al.*, Molecular Imaging True-Colour Spectroscopic Optical Coherence Tomography, *Nat. Photonics*, 2011, **5**, 744.
- 171 G. J. Lu, *et al.*, Genetically Encodable Contrast Agents for Optical Coherence Tomography, *ACS Nano*, 2020, **14**(7), 7823–7831.
- 172 V. P. Nguyen, *et al.*, Chain-like gold nanoparticle clusters for multimodal photoacoustic microscopy and optical coherence tomography enhanced molecular imaging, *Nat. Commun.*, 2021, **12**(1), 34.
- 173 Q. Li, *et al.*, Dual Ratiometric SERS and Photoacoustic Core-Satellite Nanoprobe for Quantitatively Visualizing Hydrogen Peroxide in Inflammation and Cancer, *Angew. Chem., Int. Ed.*, 2021, **60**(13), 7323–7332.



- 174 G. H. Glover, Overview of functional magnetic resonance imaging, *Neurosurg. Clin. N. Am.*, 2011, **22**(2), 133–139, vii.
- 175 D. A. Handwerker, *et al.*, The continuing challenge of understanding and modeling hemodynamic variation in fMRI, *NeuroImage*, 2012, **62**(2), 1017–1023.
- 176 E. Terreno, *et al.*, Challenges for molecular magnetic resonance imaging, *Chem. Rev.*, 2010, **110**(5), 3019–3042.
- 177 S. Na, J. J. Russin and L. Lin, *et al.*, Massively parallel functional photoacoustic computed tomography of the human brain, *Nat. Biomed. Eng.*, 2022, **6**, 584–592.
- 178 R. Ni, X. L. Deán-Ben, V. Treyer, A. Gietl, C. Hock, J. Klohs, R. M. Nitsch and D. Razansky, Coregistered transcranial optoacoustic and magnetic resonance angiography of the human brain, *Opt. Lett.*, 2023, **48**(3), 648–651.
- 179 K. P. Kubelick and S. Y. Emelianov, A Trimodal Ultrasound, Photoacoustic and Magnetic Resonance Imaging Approach for Longitudinal Post-operative Monitoring of Stem Cells in the Spinal Cord, *Ultrasound Med. Biol.*, 2020, **46**(12), 3468–3474.
- 180 L. J. Rich, *et al.*, Photoacoustic and Magnetic Resonance Imaging of Hybrid Manganese Dioxide-Coated Ultra-small NaGdF(4) Nanoparticles for Spatiotemporal Modulation of Hypoxia in Head and Neck Cancer, *Cancers*, 2020, **12**(11), 3294.
- 181 M. Sivasubramanian, *et al.*, Multimodal Magnetic Resonance and Photoacoustic Imaging of Tumor-Specific Enzyme-Responsive Hybrid Nanoparticles for Oxygen Modulation, *Front. Bioeng. Biotechnol.*, 2022, **10**, 910902.
- 182 A. B. E. Attia, *et al.*, Multispectral optoacoustic and MRI coregistration for molecular imaging of orthotopic model of human glioblastoma, *J. Biophotonics*, 2016, **9**(7), 701–708.
- 183 I. Gezginer, *et al.*, Volumetric registration framework for multimodal functional magnetic resonance and optoacoustic tomography of the rodent brain, *Photoacoustics*, 2023, **31**, 100522.
- 184 D. Wang, Y. Wu and J. Xia, Review on photoacoustic imaging of the brain using nanoprobes, *Neurophotonics*, 2016, **3**(1), 010901.
- 185 H. Bai, *et al.*, A caspase-3-activatable bimodal probe for photoacoustic and magnetic resonance imaging of tumor apoptosis *in vivo*, *Biosens. Bioelectron.*, 2022, **216**, 114648.
- 186 J. Mou, *et al.*, A facile synthesis of versatile Cu_{2-x}S nanoprobe for enhanced MRI and infrared thermal/photoacoustic multimodal imaging, *Biomaterials*, 2015, **57**, 12–21.
- 187 K. Ke, *et al.*, Copper Manganese Sulfide Nanoplates: A New Two-Dimensional Theranostic NanoplatforM for MRI/MSOT Dual-Modal Imaging-Guided Photothermal Therapy in the Second Near-Infrared Window, *Theranostics*, 2017, **7**(19), 4763–4776.
- 188 A. A. Bogdanov Jr., *et al.*, Synthesis and Testing of Modular Dual-Modality Nanoparticles for Magnetic Resonance and Multispectral Photoacoustic Imaging, *Bioconjugate Chem.*, 2016, **27**(2), 383–390.
- 189 L. S. Bouchard, *et al.*, Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**(11), 4085–4089.
- 190 J. Yu, *et al.*, Smart MoS₂/Fe₃O₄ Nanotheranostic for Magnetically Targeted Photothermal Therapy Guided by Magnetic Resonance/Photoacoustic Imaging, *Theranostics*, 2015, **5**(9), 931–945.
- 191 H. Zhang, *et al.*, A dual-mode nanoparticle based on natural biomaterials for photoacoustic and magnetic resonance imaging of bone mesenchymal stem cells *in vivo*, *RSC Adv.*, 2019, **9**(60), 35003–35010.
- 192 Y. Li, *et al.*, Carbon-Coated Magnetic Nanoparticle Dedicated to MRI/Photoacoustic Imaging of Tumor in Living Mice, *Front. Bioeng. Biotechnol.*, 2021, **9**, 800744.
- 193 H. Zhang, *et al.*, Hollow carbon nanospheres dotted with Gd-Fe nanoparticles for magnetic resonance and photoacoustic imaging, *Nanoscale*, 2021, **13**(24), 10943–10952.
- 194 Y. Zhang, *et al.*, Polydopamine-modified dual-ligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents, *Int. J. Nanomed.*, 2019, **14**, 7155–7171.
- 195 W. Zhu, *et al.*, Mn²⁺-doped prussian blue nanocubes for bimodal imaging and photothermal therapy with enhanced performance, *ACS Appl. Mater. Interfaces*, 2015, **7**(21), 11575–11582.
- 196 Q. Fan, *et al.*, Transferring biomarker into molecular probe: melanin nanoparticle as a naturally active platform for multimodality imaging, *J. Am. Chem. Soc.*, 2014, **136**(43), 15185–15194.
- 197 Y. Liu, *et al.*, Porous gold nanocluster-decorated manganese monoxide nanocomposites for microenvironment-activatable MR/photoacoustic/CT tumor imaging, *Nanoscale*, 2018, **10**(8), 3631–3638.
- 198 J. Yang, *et al.*, Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging, *Theranostics*, 2021, **11**(6), 2534–2549.
- 199 L. Zou, *et al.*, Current Approaches of Photothermal Therapy in Treating Cancer Metastasis with Nanotherapeutics, *Theranostics*, 2016, **6**(6), 762–772.
- 200 S. Wang, *et al.*, MSOT/CT/MR imaging-guided and hypoxia-manuevered oxygen self-supply radiotherapy based on one-pot MnO(2)-mSiO(2)@Au nanoparticles, *Nanoscale*, 2019, **11**(13), 6270–6284.
- 201 L. Cheng, *et al.*, FeSe(2)-Decorated Bi(2)Se(3) Nanosheets Fabricated *via* Cation Exchange for Chelator-Free (64)Cu-labeling and Multimodal Image-Guided Photothermal-Radiation Therapy, *Adv. Funct. Mater.*, 2016, **26**(13), 2185–2197.
- 202 M. M. Khalil, *et al.*, Molecular SPECT Imaging: An Overview, *Int. J. Mol. Imaging*, 2011, **2011**, 796025.
- 203 A. K. Shukla and U. Kumar, Positron emission tomography: An overview, *J. Med. Phys.*, 2006, **31**(1), 13–21.
- 204 P. J. Withers, *et al.*, X-ray computed tomography, *Nat. Rev. Methods Primers*, 2021, **1**(1), 18.
- 205 H. Lusic and M. W. Grinstaff, X-ray-computed tomography contrast agents, *Chem. Rev.*, 2013, **113**(3), 1641–1666.
- 206 G. Eda, *et al.*, Photoluminescence from chemically exfoliated MoS₂, *Nano Lett.*, 2011, **11**(12), 5111–5116.
- 207 L. Cheng, *et al.*, PEGylated WS(2) nanosheets as a multi-functional theranostic agent for *in vivo* dual-modal CT/



- photoacoustic imaging guided photothermal therapy, *Adv. Mater.*, 2014, **26**(12), 1886–1893.
- 208 W. Tang, *et al.*, Multifunctional Two-Dimensional Core-Shell MXene@Gold Nanocomposites for Enhanced Photo-Radio Combined Therapy in the Second Biological Window, *ACS Nano*, 2019, **13**(1), 284–294.
- 209 M. Chen, *et al.*, Core-shell Pd@Au nanoplates as theranostic agents for in-vivo photoacoustic imaging, CT imaging, and photothermal therapy, *Adv. Mater.*, 2014, **26**(48), 8210–8216.
- 210 Z. Li, *et al.*, Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical Sponge, *ACS Nano*, 2016, **10**(10), 9646–9658.
- 211 Y. Jin, *et al.*, Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photoacoustic bimodal imaging-guided photothermal ablation of cancer, *Biomaterials*, 2014, **35**(22), 5795–5804.
- 212 S. Yang, *et al.*, Multifunctional Bi@PPy-PEG Core-Shell Nanohybrids for Dual-Modal Imaging and Photothermal Therapy, *ACS Appl. Mater. Interfaces*, 2018, **10**(2), 1605–1615.
- 213 L. Jing, *et al.*, Prussian blue coated gold nanoparticles for simultaneous photoacoustic/CT bimodal imaging and photothermal ablation of cancer, *Biomaterials*, 2014, **35**(22), 5814–5821.
- 214 Y. Liu, *et al.*, Aggregation-Induced Absorption Enhancement for Deep Near-Infrared II Photoacoustic Imaging of Brain Gliomas *In Vivo*, *Adv. Sci.*, 2019, **6**(8), 1801615.
- 215 Y. Wang, *et al.*, *In Vivo* Photoacoustic/Single-Photon Emission Computed Tomography Imaging for Dynamic Monitoring of Aggregation-Enhanced Photothermal Nanoparticles, *Anal. Chem.*, 2019, **91**(3), 2128–2134.
- 216 M. Yao, *et al.*, Engineering of SPECT/Photoacoustic Imaging/Antioxidative Stress Triple-Function Nanoprobe for Advanced Mesenchymal Stem Cell Therapy of Cerebral Ischemia, *ACS Appl. Mater. Interfaces*, 2020, **12**(34), 37885–37895.
- 217 W. Shang, *et al.*, Core-Shell Gold Nanorod@Metal-Organic Framework Nanoparticles for Multimodality Diagnosis of Glioma, *Adv. Mater.*, 2017, **29**(3), 1604381.
- 218 X. Liang, *et al.*, Activatable near infrared dye conjugated hyaluronic acid based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy, *Biomaterials*, 2017, **132**, 72–84.
- 219 B. Wu, *et al.*, Gadolinium-chelate functionalized bismuth nanotheranostic agent for *in vivo* MRI/CT/PAI imaging-guided photothermal cancer therapy, *Biomaterials*, 2018, **159**, 37–47.
- 220 Y. Cheng, *et al.*, Glutathione-Mediated Clearable Nanoparticles Based on Ultrasmall Gd(2)O(3) for MSOT/CT/MR Imaging Guided Photothermal/Radio Combination Cancer Therapy, *Mol. Pharmaceutics*, 2019, **16**(8), 3489–3501.
- 221 Y. Wang, *et al.*, Oxygen-supplementing mesoporous polydopamine nanosponges with WS(2) QDs-embedded for CT/MSOT/MR imaging and thermoradiotherapy of hypoxic cancer, *Biomaterials*, 2019, **220**, 119405.
- 222 X. Men, *et al.*, Thermosensitive Polymer Dot Nanocomposites for Trimodal Computed Tomography/Photoacoustic/Fluorescence Imaging-Guided Synergistic Chemo-Photothermal Therapy, *ACS Appl. Mater. Interfaces*, 2020, **12**(46), 51174–51184.
- 223 T. Liu, *et al.*, Iron oxide decorated MoS₂ nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy, *ACS Nano*, 2015, **9**(1), 950–960.
- 224 J. Lin, *et al.*, Multimodal-Imaging-Guided Cancer Phototherapy by Versatile Biomimetic Theranostics with UV and γ -Irradiation Protection, *Adv. Mater.*, 2016, **28**(17), 3273–3279.
- 225 M. Yang, *et al.*, Dragon fruit-like biocage as an iron trapping nanopatform for high efficiency targeted cancer multimodality imaging, *Biomaterials*, 2015, **69**, 30–37.
- 226 S. Wang, *et al.*, Core-Satellite Polydopamine–Gadolinium–Metallofullerene Nanotheranostics for Multimodal Imaging Guided Combination Cancer Therapy, *Adv. Mater.*, 2017, **29**(35), 1701013.
- 227 C. Xu, *et al.*, Long circulating reduced graphene oxide-iron oxide nanoparticles for efficient tumor targeting and multimodality imaging, *Nanoscale*, 2016, **8**(25), 12683–12692.
- 228 Y. Zhang, *et al.*, Surfactant-Stripped Frozen Pheophytin Micelles for Multimodal Gut Imaging, *Adv. Mater.*, 2016, **28**(38), 8524–8530.
- 229 J. J. Vaquero and P. Kinahan, Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems, *Annu. Rev. Biomed. Eng.*, 2015, **17**, 385–414.
- 230 Y. Zhang, *et al.*, Non-invasive multimodal functional imaging of the intestine with frozen micellar naphthalocyanines, *Nat. Nanotechnol.*, 2014, **9**(8), 631–638.
- 231 S. Hussain, *et al.*, Modern Diagnostic Imaging Technique Applications and Risk Factors in the Medical Field: A Review, *BioMed Res. Int.*, 2022, **2022**, 5164970.
- 232 D. Calle, P. Ballesteros and S. Cerdán, Advanced Contrast Agents for Multimodal Biomedical Imaging Based on Nanotechnology, *Methods Mol. Biol.*, 2018, **1718**, 441–457.
- 233 D. Delbeke, *et al.*, Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions, *Semin. Nucl. Med.*, 2009, **39**(5), 308–340.
- 234 E. V. Dizendorf, *et al.*, Application of Oral Contrast Media in Coregistered Positron Emission Tomography—CT, *Am. J. Roentgenol.*, 2002, **179**(2), 477–481.
- 235 W. Choi, *et al.*, Recent Advances in Contrast-Enhanced Photoacoustic Imaging: Overcoming the Physical and Practical Challenges, *Chem. Rev.*, 2023, **123**(11), 7379–7419.
- 236 X.-f. Shi, *et al.*, Multimodal Contrast Agents for Optoacoustic Brain Imaging in Small Animals, *Front. Bioeng. Biotechnol.*, 2021, **9**, 746815.



- 237 S.-V. Bodea and G. G. Westmeyer, Photoacoustic Neuroimaging - Perspectives on a Maturing Imaging Technique and its Applications in Neuroscience, *Front. Neurosci.*, 2021, **15**, 655247.
- 238 L. Lin and L. V. Wang, The emerging role of photoacoustic imaging in clinical oncology, *Nat. Rev. Clin. Oncol.*, 2022, **19**(6), 365–384.
- 239 X. L. Deán-Ben, *et al.*, Deep optoacoustic localization microangiography of ischemic stroke in mice, *Nat. Commun.*, 2023, **14**(1), 3584.
- 240 Z. Chen, *et al.*, Widefield fluorescence localization microscopy for transcranial imaging of cortical perfusion with capillary resolution, *Opt. Lett.*, 2020, **45**(13), 3470–3473.
- 241 N. Liu, *et al.*, Croconaine-based nanoparticles enable efficient optoacoustic imaging of murine brain tumors, *Photoacoustics*, 2021, **22**, 100263.
- 242 Q. Zhou, *et al.*, Three-dimensional wide-field fluorescence microscopy for transcranial mapping of cortical microcirculation, *Nat. Commun.*, 2022, **13**(1), 7969.

